A METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS

Abstract: The present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an immunoglobulin or Ig fusion protein molecule to the subject, the immunoglobulin molecule having a variable region and a constant region, the immunoglobulin molecule being modified prior to administration by inactivation of at least a portion of the constant region.

Description: A METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED TOXICITY RESULTING FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. TECHNICAL FIELD OF THE INVENTION The present invention relates to methods for inhibiting or reducing immunoglobulin- induced toxicity resulting from therapy or in vivo diagnosis. Specifically, in lieu of using unmodified antibodies or recombinant binding proteins for in vivo use, the invention provides the use of modified antibodies or recombinant binding proteins which have been structurally altered in the constant domain so that upon administration immunoglobulin-induced toxicity is reduced or inhibited. BACKGROUND OF THE INVENTION Over the years investigators have attempted to harness the immune system for therapeutic use. Immunoglobulin (Ig) molecules which constitute an important part of the immune system are of great interest because they (1) react with a diverse family of ligands, (2) possess different effector functions and (3) are of great biological importance. Despite its potential, a persistent problem with immunoglobulin immunotherapy has been, among other problems, the toxic effect to normal cells of using antibodies which recognize both normal and diseased cells. This problem is far-reaching because the majority of antibodies presently available recognize a target located on both normal and diseased cells (Slavin-Chiorini, et al., Int. J. Cancer 53: 97-103 (1993)). The constant region can promote cell death through antibody dependent cell mediated cytotoxicity (ADCC) or by complement dependent cytotoxicity (CDC). Despite the deletion of portions of the constant region, particularly the CH 2 domain, the antigen binding function can be retained (D. Yelton, M. Scharf, Mutant monoclonal antibody with alterations in biological functions, J. Exp. Methods 156:1 131-1 148 (1982)). Others have generated a CH 2 -deleted antibody (Mueller et al., Proc. Natl. Acad. Sci. USA 87: 5702-5705 (1990)). Their findings provide that the CH 2 -deleted antibody was cleared from the blood of tumor-bearing mice much faster than the corresponding intact antibody. Other in vivo findings also confirmed that a CH 2 - deleted antibody, designated chl4.18DCH2, is a potentially useful reagent for radioimmunodetection of human tumors because of its reduced immunogenicity, increased target specificity, and rapid clearance from circulation (Mueller et al., Proc. Natl. Acad. Sci. USA 87: 5702-5705 (1990). Generally, whole antibody molecules are composed of two heavy (H) and two light (L) chains which are held together by covalent bonds (disulfide) and non-covalent interactions. Each chain contains a variable region (V) and a constant region (C). The variable regions at the amino termini of the two chains form the antigen binding region. The constant region of the H chain has three components or domains. Occasionally, the first constant region domain (CHi) interacts with the C region of the L chain through hydrophobic interactions and generally a disulfide bond, depending on isotype. The next C region stretch is the hinge-acting disulfide bond stably introduced between two H chains. The second constant region domain (CH 2 ) is adjacent to the hinge region. CH 2 contains sequences important for effector functions of the antibody, such as the sequences responsible for complement fixation, and Fc receptor binding The third constant region domain (CH 3 ) is located at the carboxyl terminus of the H chain, and is considered to play an important role in H chain assembly as well as some C region functions. Today many antibodies in clinical trials are directed against tumor associated antigens. Most tumor associated antigens are not tumor specific but are also generally found on the cell surface of some normal, non-tumorigenic cells. The clinical use of some antibodies directed against tumor associated antigens are limited because of the toxicity associated with their use. Therefore, there is a need for methods for inhibiting toxicity associated with immunoglobulin use in the field of disease therapy (e.g., therapy for tumors, kidney disease, and the like) and in vivo diagnosis. We addressed this need by discovering methods for inhibiting or reducing toxicity to normal cells generally associated with immunoglobulin immunotherapy or in vivo diagnosis, wherein the immunoglobulin recognizes both diseased and normal cells. Our discovery involves generating immunoglobulin molecules or Ig fusion proteins having structurally altered constant regions which inhibit or reduce immunoglobulin-induced toxicity. SUMMARY OF THE INVENTION The present invention provides methods for inhibiting immunoglobulin-induced toxicity by using known immunoglobulin or Ig fusion protein molecules which are structurally altered in their constant regions so that the resulting structurally altered immunoglobulin or Ig fusion protein molecules exhibit reduced or inhibited toxicity in vivo compared to their original unmodified counterparts. Structural alteration of the constant region may be effected in a number of ways as long as it results in reducing or inhibiting immunoglobulin-induced toxicity. In accordance with the practice of the invention, structural alteration of the constant region is effected by deletion of the entire constant region. In another embodiment, only the CH 2 domain is deleted. In another embodiment, only that portion of the CH 2 domain that binds the Fc receptor is deleted. In yet another embodiment, only that portion of the CH 2 domain that binds the complement component Clq is deleted. Alternatively, in another embodiment, multiple deletions in discrete Fc receptor and complement component binding domains are effected. Alternatively, structural alteration is effected by single or multiple mutations in the CH 2 domain such as amino acid insertions and substitutions. The mutation or mutations must result in inhibiting immunoglobulin-induced toxicity. By way of example, the amino acids in multiple toxicity associated domains in the constant region can be altered so as to render the constant region unable to mediate a ADCC response or activate complement thereby inhibiting immunoglobulin induced toxicity resulting from immunotherapy. Alternatively, multiple amino acids in a single toxicity associated domain in the constant region can be altered. Further alternatively, structural alteration can be effected by isotype switching resulting in an altered immunoglobulin molecule that either does not induce toxicity or induces some limited toxicity but does not cause a harmful effect. For example, isotype switching can result in the constant region being unable to mediate a CDC or ADCC response or some other activity which mediates toxicity. BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a line graph showing plasma clearance in high Le expressing dogs using chimeric BR96 versus constant region mutant of cBR96-2. Figure 2 is a schematic diagram of a plasmid designated pTWD-cJVK.Ll including the chimeric (c)BR96-light chain (SEQ ID NO. 11). Figure 3 is a schematic diagram of a plasmid designated pDlόhJl.Ll including the human (h)BR96-light chain (SEQ ID NO. 13). Figure 4 is a schematic diagram of a plasmid, designated pD17-hJml4-dCH2.Hl, of hBR96-2A (i.e., human mutant BR96 having the HI, H2, and H3 mutations and the CH 2 deletion (PCT Application No. 95/305444, published March 6, 1996)). Figure 5 is a schematic diagram of a plasmid, designated pD17-cJ-dCH2.Hl, of cBR96-A (SEQ ID NO. 10) (i.e., chimeric BR96 having the CH 2 deletion (PCT Application No. 95/305444, published March 6, 1996)). Figure 6 is a schematic diagram of a plasmid, designated pD17-cJ.Hl, of cBR96. Figure 7 is a line graph showing the results of an ELISA assay of (1) hBR96-2A- Dox to Le y (closed diamond), (2) hBR96-2A to Le y (96:0006A2 R/A)(closed square), (3) hBR96-2A to Le y (96:0006B R/A)(closed triangle), and BR96-Dox to Le y (X). Figure 8 is a line graph showing the results of an ELISA assay of (1) BR96-A-Dox to Le y (closed diamond), (2) chiBR96 to Le y (closed square), (3) cBR96-A to Le y (96:0003 R/A)(closed triangle), and cBR96-Dox to Le y (X). Figures 9a-c are schematic diagrams showing the steps for deleting a CH 2 domain. Figures lOa-c are schematic diagrams showing the construction of BR96 IgGl CH 2 domain point mutations. Figure 11 is a schematic diagram showing the construction of the pNgl/14 vector. Figure 12 is a schematic diagram showing the construction of pD17-hBR96-2. Figure 13 is a schematic diagram showing the construction of pD17-hJml4- dCH2.Hl. Figure 14 is the nucleic acid sequence of pD17-cJ-dCH2.Hl, the plasmid shown in Figure 5, chimeric BR96 having the CH 2 deletion. Figure 15 is a line graph showing the results of an ELISA assay comparing whole chiBR96 and deleted CH 2 chiBR96 on Le y . Figure 16 is a description of the seven structural alterations. Figure 17 is a schematic diagram of a plasmid designated pD17-hGlb. Figure 18 is the nucleic acid sequence of pD17-hJml4.Hl . Figure 19 is the nucleic acid sequence of pD17-hGlb. Figure 20 is a line graph showing complement dependent cytotoxicity. In the legend, the closed square is hBR96-l; closed diamond is hBR96-2B; closed circle is hBR96-2C; closed triangle is hBR96-2D; open square is hBR96-2H; open circle is hBR96-2A and open triangle is 2B8, anύ-Pseudonomas aeruginosa flagella type b mAb, negative control. Figure 21 is a line graph showing antibody dependent cell-mediated cytotoxity. In the legend, the closed square is hBR96-l ; closed diamond is hBR96-2B; closed circle is hBR96-2C; closed triangle is hBR96-2D; open square is hBR96-2H; open circle is hBR96-2A and open triangle is 2B8, anύ-Pseudonomas aeruginosa flagella type b monoclonal antibody (mAb), negative control. Figure 22 is a line graph showing binding activity of hBR96-2 constant region mutants on LeY-HSA. In the legend, the solid diamond is hBR96-l ; solid square is hBR96-2A (CH2 deletion); solid triangle is hBR96-2B (235, 237 mutations); open square is hBR96-2C (318, 320, 322 mutations); open circle is hBR96-2D (331 mutation); and open triangle is hBR96-2H (235, 237, 318, 320, 322, 331 mutations). Figure 23 is a line graph showing binding activity of hBR96-2 constant region mutants on LNFPIII-BSA. LNFPIII is a lacto-N-fucopentasose, a Lewis X trisaccharide with an additional lactose spacer (V Labs, Covington, LA). In the legend, the solid diamond is hBR96-l ; solid square is hBR96-2A (CH2 deletion); solid triangle is hBR96-2B (235, 237 mutations); open square is hBR96-2C (318, 320, 322 mutations); open circle is hBR96-2D (331 mutation); and open triangle is hBR96-2H (235, 237, 318, 320, 322, 331 mutations). Figures 24A and 24B provide a strategy for introducing multiple mutations by RPCR. (A) Diagram of he 1.4 kpb IgG heavy chain region showing the hinge CH 2 and CH 3 domains as boxed regions. Site-specific mutations to be introduced into CH 2 positions LI, L2, and L3 are encoded by complementary sets of mutant PCR primers (Al and A2; Bl and B2; and Cl and C2). The asterisks (*) indicate the number of amino acid changes introduced at each L position. The two PCR primers, Rs (Recombination -sense) and Ra (Recombination-antisense), flank the Eco-47-III restriction sites and mediate homologous recombination with vector ends. The 3' ends of the oligonucleotides are represented by arrowheads. (B) A three-way homologous recombination event between fragments RsA2, AIRa and the linearized vector produces the LI mutant IgG. Two distally located sets of mutations (LI and L2) are simultaneously introduced by increasing the number of recombining PCR produces as is shown in the four- way recombination of RsA2, A1B1, BIRa with vector. Figure 25 is a gel showing Eco-47-III restriction endonuclease analysis of DNAs prepared from colonies generated by multiple PCR fragment RPCR. Lane M: lkb ladder DNA marker (GIBCO BRL Life Science Technology). Lanes 1-12: Twelve randomly selected colonies resulting from quadruple homologous recombination events were used to prepare plasmid and digested with Eco47-III. Clones 1, 2, 6 and 9 contain the fully assembled 1.4 kpb insert. Figure 26 provides the amino acid sequence for hBR96-2 heavy-chain variable region and the human IgGl constant region. Figure 27 provides the amino acid sequence for hBR96-2A heavy-chain variable region and the human IgGl constant region. Figure 28 provides the amino acid sequence for chi BR96 heavy-chain variable region and the human IgGl constant region without the CH 2 domain. DF ATI-F-D DESCRIPTION OF THE INVENTION DEFINITIONS As used herein the term "inhibiting immunoglobulin-induced toxicity" means to reduce or alleviate symptoms generally associated with toxicity caused by immunoglobulin or Ig fusion protein therapy, e.g., toxicity mediated by effector functions of the Fc receptor. For example, BR96 antibody recognizes and binds BR96 antigen which is found at some levels in the gastrointestinal tract and at elevated levels in tumors (as compared to the gastrointestinal tract of normal tissues). The binding of BR96 antibody to BR96 antigen in vivo causes symptoms associated with gastrointestinal toxicity. These symptoms include rapid onset of vomiting, often with blood, and nausea. In humans the bleeding is limited to the fundus of the stomach, causing erosion of the superficial mucosa of the stomach. The pathology of the wound is limited and resolves. However, the extreme nature of the nausea and vomiting, unrelieved by anti-emetics, defines it as the dose-limiting toxicity. For highly elevated levels of other antigens found in the central nervous system (CNS), liver, and other locations, the toxicity will be characterized by symptoms other than those described above. As used herein the term "immunoglobulin molecule" can be produced by B cells or be generated through recombinant engineering or chemical synthetic means. Examples of immunoglobulin molecules include (1) antibodies, e.g., polyclonal and monoclonal antibodies, chimeric or humanized, and (2) recombinant Ig containing binding proteins, e.g., Ig fusion proteins. Recombinant Ig containing binding proteins include cell surface proteins, e.g., CD antigens (in one embodiment, CTLA4), to which an Ig tail is joined. As used herein the terms "structurally altered" or "structural alteration" means manipulating the constant region so that the resulting molecule or protein exhibits a diminished ability to induce toxicity. Structural alteration can be by chemical modification, proteolytic alteration, or by recombinant genetic means. Recombinant genetic means may include, but is not limited to, the deletion, insertion and substitution of amino acid moieties. As used herein the terms "multiple toxicity associated domains" means more than one discrete toxicity associated domain. As there appear to be at least two toxicity associated domains in the immunoglobulin molecule, one roughly localized to amino acids 231-238 and another roughly localized to amino acids 310-331, an example of the structural alteration of multiple toxicity associated domains comprises the insertion, substitution or deletion of amino acid residues in both of these domains. This definition excludes structural alterations targeting a single toxicity associated domain. Merely by way of example, the constant region of the immunoglobulin molecule can be structurally altered so that the molecule no longer mediates a CDC or ADCC response. However, the methods of the invention encompasses the use of structurally altered immunoglobulin molecules regardless of whether it mediates a CDC or ADCC response. The underlying requirement is that the altered molecule must inhibit immunoglobulin-induced toxicity. Structural alteration can be effected in a number of ways. For example, structural alteration can be effected by deletion of the entire constant region. Alternatively, structural alteration can be effected by deletion of the entire CH 2 domain of the constant region. In this instance, deletion of the entire CH 2 domain may render the molecule unable to (1) bind an Fc receptor thereby eliminating the molecule's possibility of mediating antibody-dependent cellular cytotoxicity (ADCC), (2) bind Clq, or (3) activate complement. Alternatively, structural alteration can be effected by deletion of only that portion of the CH 2 domain that binds the Fc receptor or complement. Further alternatively, a single mutation or multiple mutations such as substitutions and insertions in the CH 2 domain can be made. The underlying requirement of any mutation is that it must inhibit, diminish, or block immunoglobulin-induced toxicity. For example, this can be achieved by mutating the constant region such that the altered molecule is rendered unable to mediate a CDC response or an ADCC response, or to activate complement. Alternatively, structural alteration can be effected by isotype switching (also known as class switching) so that the altered molecule does not induce toxicity in the subject. In one embodiment, the constant region of the immunoglobulin is structurally altered so that it no longer binds the Fc receptor or a complement component, e.g., switching a molecule's original IgG isotype from IgGl to IgG4. Isotype switching can be effected regardless of species, i.e., an isotype from a non- human being can be switched with an isotype from a human being (E.D. Finkelman et al. (1990) Annu. Rev. Immunol. 8:303-333; T. Honjo et al. (1979) Cell 18: 559- 568; T. Honjo et al. In "Immunoglobulin Genes" pp. 124-149 Academic Press, London)). As used herein the term "Ig fusion protein" means any recombinantly produced antigen or ligand binding domain having a constant region which can be structurally altered. As used herein "cytotoxic agent" includes antimetabolites, alkylating agents, anthracyclines, antibiotics, anti-mitotic agents, and chemotherapeutic agents. Specific examples within these groups include but are not limited to ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, supporin, gelonin, PE40, bryodin, dihydroxy anthracin dione, actinomycin D, and 1-dehydrotestosterone. As used herein the term "BR96" refers to (1) the whole BR96 monoclonal antibody disclosed in PCT No. 95/305444, published March 6, 1996, (2) chimeric BR96 monoclonal antibody disclosed in PCT No. 95/305444, published March 6, 1996, or (3) BR96 mutant molecules disclosed in PCT No. 95/305444, published March 6, 1996. As used herein, "treating" means to (1) provide tumor regression so that the tumor is not palpable for a period of time (standard tumor measurement procedures may be followed (A.B. Miller et al. "Reporting results of cancer treatment" Cancer 47:207- 214 (1981)); (2) stabilize the disease; or (3) provide any clinically beneficial effects. As used herein, an "effective amount" is an amount of the antibody, immunoconjugate, or recombinant molecule which kills cells or inhibits the proliferation thereof. As used herein, "administering" means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular or subcutaneous administration, or the implantation of a slow-release device such as a miniosmotic pump, to the subject. As used herein, "pharmaceutically acceptable carrier" includes any material which when combined with the antibody retains the antibody's specificity or efficacy and is non-reactive with the subject's immune system. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Other carriers may also include sterile solutions, tablets including coated tablets and capsules. Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known conventional methods. As used herein, "mutation" means a single amino acid or nucleic acid mutation or multiple mutations by whatever means, e.g., homologous recombination, error prone PCR, or site directed mutagenesis. In order that the invention herein described may be more fully understood, the following description is set forth. METHODS OF THE PRESENT INVENTION The present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulin during therapy or in vivo diagnosis. For example, the methods of the invention would be useful to minimize the toxicity associated with prolonged clinical exposure to immunoglobulin use during or after tumor imaging with radiolabeled antibodies. In accordance with the practice of this invention, the subject includes, but is not limited to, human, equine, porcine, bovine, murine, canine, feline, and avian subjects. Other warm blooded animals are also included in this invention. This method comprises administering an immunoglobulin molecule to the subject. The immunoglobulin can be IgG, IgM, or IgA. IgG is preferred. In one embodiment of the invention, the immunoglobulin molecule recognizes and binds Le y . In another embodiment, the immunoglobulin recognizes and binds Le\ In a further embodiment, the immunoglobulin is a monoclonal antibody BR96 produced by the hybridoma deposited on February 22, 1989 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852 and accorded ATCC Accession No.: HB 10036. In yet another embodiment, the immunoglobulin is a chimeric antibody ChiBR96 produced by the hybridoma deposited on May 23, 1990, with the ATCC, 12301 Parklawn Drive, Rockville, MD 20852 and accorded ATCC Accession No.: HB 10460. In accordance with the practice of the invention, the immunoglobulin can be a bispecific antibody with a binding specificity for two different antigens, one of the antigens being that with which the monoclonal antibody BR96 produced by the hybridoma having the identifying characteristics of HB 10036 as deposited with the ATCC binds. Also, in accordance with the practice of the invention, the immunoglobulin can be an anti-idiotypic antibody. As required by the invention, at least a portion of the constant region of the immunoglobulin molecule is structurally altered. Structural alteration can be effected by a number of means. In one embodiment, the entire constant region, i.e., CH b CH 2 , and CH 3 domains, can be deleted. In another embodiment, only the CH 2 domain is deleted from the immunoglobulin molecule (e.g., cBR96-A (Figure 5), hBR96-2A (Figure 4). In this embodiment, the CH 2 deletion may result in a molecule unable to bind the Fc receptor or a complement component. In another embodiment, only that portion of the CH 2 domain which binds the complement component Clq is deleted. In yet another embodiment, mutations in specific portions of the CH 2 domain are made. For example, the immunoglobulin molecule may be modified by structurally altering multiple toxicity associated domains in the constant region so that immunoglobulin-induced toxicity is inhibited. A discussion of such mutations are further found hereinafter. Regardless of the means, the underlying requirement for any structural alteration of the constant region is that immunoglobulin-induced toxicity is substantially reduced or inhibited. In one embodiment, immunoglobulin-induced toxicity is inhibited by structurally altering the constant region such that the molecule's ability to mediate a CDC response or ADCC response and/or activate the complement cascade is prevented or inhibited. Methods for determining whether the molecule is able to inhibit a CDC response are well known, e.g., one method involves a Cr-release test (H. Garrigues et al. Int. J. Cancer 29:511 (1982); I. Hellstrom et al. PNAS 82:1499 (1985)). Methods for determining whether the molecule is able to inhibit an ADCC response are well known (I. Hellstrόm et al. PNAS 82:1499 (1985)). Methods for determining whether the molecule is able to activate a complement cascade are well known. In another embodiment of the invention, the method comprises administering to the subject an Ig fusion protein having a structurally altered constant region. Structural alteration of the constant region may include deletion of the entire C region or portions thereof, e.g., alteration of the CH 2 domain so that the altered molecule no longer binds the Fc receptor or a complement component. The invention further provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject. The method comprises administering to the subject an antibody which has been modified so that at least a portion of the constant region has been structurally altered as discussed supra. In one embodiment, the antibody recognizes and binds Le y . In another embodiment, the antibody recognizes and binds to Le x . In accordance with the practice of this invention, the antibody can be monoclonal antibody BR96 produced by the hybridoma having the identifying characteristics of HB 10036 as deposited with the ATCC. Alternatively, the antibody can be chimeric antibody ChiBR96 produced by the hybridoma having the identifying characteristics of HB 10460 as deposited with the ATCC. Further, the antibody can be a bispecific antibody with a binding specificity for two different antigens, one of the antigens being that with which the monoclonal antibody BR96 produced by the hybridoma having the identifying characteristics of HB 10036 as deposited with the ATCC binds. Additionally, the present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy for a disease in a subject. The disease will vary with the antigen sought to be bound. Examples of diseases include but are not limited to immunological diseases, cancer, cardiovascular diseases, neurological diseases, dermatological diseases or kidney disease. This method comprises the following steps. Step one provides selecting an antibody for a target. Generally, the target is associated with the disease and the antibody directed to the target is known. For example, the target can be the BR96 antigen and the antibody selected is BR96. Step two of this method provides structurally altering the constant region of the antibody so selected so that immunoglobulin induced toxicity is inhibited. Inactivation can include any of the means discussed above. For example, inactivation can be effected by structurally altering multiple toxicity associated domains in the CH 2 domain of the constant region of the Ig protein so selected. Step three of this method provides administering the structurally altered antibody of step two to the subject under conditions that the structurally altered antibody recognizes and binds the target and that such binding directly or indirectly alleviates symptoms associated with the disease. In accordance with the invention, in one embodiment step one provides selecting an Ig fusion protein for a target. Further, the method provides mutating the Ig fusion protein so selected by structurally altering the CH 2 domain of the constant region of the Ig protein by the same means discussed above. The invention further provides methods to treat human carcinoma. For example, the immunoglobulin, antibody, or Ig fusion protein discussed above can be used in combination with standard or conventional treatment methods such as chemotherapy, radiation therapy or can be conjugated or linked to a therapeutic drug, or toxin, as well as to a lymphokine or a tumor-inhibitory growth factor, for delivery of the therapeutic agent to the site of the carcinoma. Techniques for conjugating therapeutic agents to immunoglobulins are well known (see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrόm et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982)). Alternatively, the structurally altered antibody or Ig fusion protein can be coupled to high-energy radiative agents, e.g., a radioisotope such as l31 I; which, when localized at the tumor site, results in a killing of several cell diameters (see, e.g., Order, "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985)). According to yet another embodiment, the structurally altered BR96 antibody can be conjugated to a second antibody to form an antibody heteroconjugate for the treatment of tumor cells as described by Segal in United States Patent 4,676,980. Still other therapeutic applications for the structurally altered antibody or Ig fusion protein of the invention include conjugation or linkage, e.g., by recombinant DNA techniques or protein chemical techniques, to an enzyme capable of converting a prodrug into a cytotoxic drug and the use of that antibody-enzyme conjugate in combination with the prodrug to convert the prodrug to a cytotoxic agent at the tumor site (see, e.g., Senter et al., "Anti-Tumor Effects Of Antibody-alkaline Phosphatase", Proc. Natl. Acad. Sci. USA, 85:4842-46 (1988); "Enhancement of the in vitro and in vivo Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody- Alkaline Phosphatase Conjugates", Cancer Research 49:5789-5792 (1989); and Senter, "Activation of Prodrugs by Antibody-Enzyme Conjugates: A New Approach to Cancer Therapy," FASEB J. 4:188-193 (1990)). It is apparent therefore that the present invention encompasses pharmaceutical compositions including immunoglobulin molecules, antibodies, and Ig fusion proteins all having structurally altered CH 2 domains, and their use in methods for treating human carcinomas. For example, the invention includes pharmaceutical compositions for use in the treatment of human carcinomas comprising a pharmaceutically effective amount of a structurally altered BR96 and a pharmaceutically acceptable carrier. The compositions may contain the structurally altered antibody or Ig fusion protein or antibody fragments, either unmodified, conjugated to a therapeutic agent (e.g., drug, toxin, enzyme or second antibody). The compositions may additionally include other antibodies or conjugates for treating carcinomas (e.g., an antibody cocktail). The compositions of the invention can be administered using conventional modes of administration including, but not limited to, intrathecal, intravenous, intraperitoneal, oral, intralymphatic or administration directly into the tumor. Intravenous administration is preferred. The composition of the invention can be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of administration and the therapeutic application. The compositions of the invention also preferably include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate. In accordance with the practice of the invention, the pharmaceutical carrier can be a lipid carrier. The lipid carrier can be a phospholipid. Further, the lipid carrier can be a fatty acid. Also, the lipid carrier can be a detergent. As used herein, a detergent is any substance that alters the surface tension of a liquid, generally lowering it. In one example of the invention, the detergent can be a nonionic detergent. Examples of nonionic detergents include, but are not limited to, polysorbate 80 (also known as Tween 80 or (polyoxyethylenesorbitan monooleate), Brij, and Triton (for example Triton WR-1339 and Triton A-20). Alternatively, the detergent can be an ionic detergent. An example of an ionic detergent includes, but is not limited to, alkyltrimethylammonium bromide. Additionally, in accordance with the invention, the lipid carrier can be a liposome. As used in this application, a "liposome" is any membrane bound vesicle which contains any molecules of the invention or combinations thereof. The most effective mode of administration and dosage regimen for the compositions of this invention depends upon the severity and course of the disease, the patient's health and response to treatment and the judgment of the treating physician. The interrelationship of dosages for animals of various sizes and species and humans based on mg/m of surface area is described by Freireich, E.J., et al. Cancer Chemother., Rep. 50 (4): 219-244 (1966). Adjustments in the dosage regimen can be made to optimize the tumor cell growth inhibiting and killing response, e.g., doses can be divided and administered on a daily basis or the dose reduced proportionally depending upon the situation (e.g., several divided doses can be administered daily or proportionally reduced depending on the specific therapeutic situation). THE MOLECULES OF THE INVENTION The present invention provides structurally altered BR96 or BR96 Ig fusion proteins. Structurally altered BR96 antibodies or Ig fusion proteins have the variable region of BR96 and a modified constant region. This modification provides structurally altered BR96 antibodies or Ig fusion proteins with the ability to inhibit immunoglobulin-induced toxicity. Various embodiments of structurally altered BR96 or BR96 Ig fusion proteins have been made. In one embodiment, designated cBR96-A, the entire CH 2 domain of cBR96 was deleted. CBR96-A is expressed by the plasmid having the sequence shown in SEQ. ID. NO. 10. cBR96 is expressed by a plasmid having the sequence in SEQ ID NO. 9. In another embodiment, designated hBR96-2A, the entire CH 2 domain of hBR96 was deleted. hBR96-A is expressed by the plasmid having the sequence shown in SEQ. ID. NO. 12. hBR96 is a mutant BR96 having the HI, H2, and H3 mutations described in PCT Application No. 95/305444, published March 6, 1996. In yet another embodiment, designated hBR96-2B, the leucine residue located at amino acid position 235 is mutated to alanine. Additionally, the glycine residue located at amino acid position 237 is mutated to alanine. The amino acid position numbering used is described in Kabat et al. Sequences of Proteins of Immunological Interest 5th Edition (1991) United States Department of Health and Human Services. In a further embodiment, designated hBR96-2C, the glutamic acid residue at position 318 is mutated to serine; the lysine residue located at position 320 is mutated to serine; and the lysine residue located at position 322 is mutated to serine using standard protocols (Alexander R. Duncan and Greg Winter "The binding site for Clq on IgG" Nature 332:738 (1988)). In another embodiment, designated hBR96-2D, the proline residue at position 331 is mutated to alanine (M-H. Tao et al., "Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation" J. Exp. Med. 178:661-667 (1993); Y. Xu et al., "Residue at position 331 in the IgGl and IgG4 domains contributes to their differential ability to bind and activate complement" J. Biol. Chem. 269:3469-3474 (1994)). In an additional embodiment, designated hBR96-2E, the leucine residue at position 235 is mutated to alanine; the glycine residue located at position 237 is mutated to alanine; the glutamic acid residue located at position 318 is mutated to serine; the lysine residue located at position 320 is mutated to serine; and the lysine residue located at position 322 is mutated to serine (A. Morgan et al., "The N-terminal end of the CH 2 domain of chimeric human IgGl anti-HLA-DR is necessary for Clq, Fc(gamma)RI and Fc(gamma)RIII binding" Immunol. 86:319-324 (1995)). In yet a further embodiment, designated hBR96-2F, the leucine residue located at position 235 is mutated to alanine; the glycine residue located at position 237 is mutated to alanine; and the proline residue located at position 331 is mutated to alanine. In yet another embodiment, designated hBR96-2G, the glutamic acid residue located at position 318 is mutated to serine; the lysine residue located at position 320 is mutated to serine; the lysine residue located at position 322 is mutated to serine; and the proline residue located at position 331 is mutated to alanine. In another embodiment, designated hBR96-2H, the leucine residue located at position 235 is mutated to alanine; the glycine residue located at position 237 is mutated to alanine; the glutamic acid residue at position 318 is mutated to serine; the lysine residue located at position 320 is mutated to serine; the lysine residue located at position 322 is mutated to serine; and the proline residue located at position 331 is mutated to alanine. Depending on its form, a structurally altered BR96 antibody or fusion protein can be a monofunctional antibody, such as a monoclonal antibody, or bifunctional antibody, such as a bispecific antibody or a heteroantibody. The uses of structurally altered BR96, i.e., as a therapeutic or diagnostic agent, will determine the different forms of structurally altered BR96 which is made. Several options exists for antibody expression. Immunoexpression libraries can be combined with transfectoma technology, i.e., the genes for the Fab molecules derived from the immunoglobulin gene expression library can be connected to the desired constant-domain exons. These recombinant genes can then be transfected and expressed in a transfectoma that would secrete an antibody molecule. Once produced, the polypeptides of the invention can be modified, i.e., by amino acid modifications within the molecule, so as to produce derivative molecules. Such derivative molecules would retain the functional property of the polypeptide, namely, the molecule having such substitutions will still permit the binding of the polypeptide to the BR96 antigen or portions thereof. It is a well-established principle of protein chemistry that certain amino acid substitutions, entitled "conservative amino acid substitutions," can frequently be made in a protein without altering either the conformation or the function of the protein. Amino acid substitutions include, but are not necessarily limited to, amino acid substitutions known in the art as "conservative". Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing p 's of these two amino acid residues are not significant. Still other changes can be considered "conservative" in particular environments. In one embodiment of the present invention, the polypeptide is substantially pure, i.e., free of other amino acid residues which would inhibit or diminish binding of the polypeptide to its target and would inhibit or reduce gastrointestinal toxicity which are normally exhibited during or after antibody therapy. NUCLEIC ACID MOLECULES ENCODING THE PRESENT INVENTION The nucleotide sequences and the amino acid sequences of the variable and constant regions of BR96 are known. The sequence for the immunoglobulin constant region is known and provided in Figure 18. Specific mutations in the constant region of the BR96 antibody were made. Nucleic acid molecules encoding the seven mutants described above (hBR96-2B through hBR96-2H) are as follows. In hBR96-2B, alanine at amino acid positions 235 and 237 is encoded by codons GCU, GCC, GCA, or GCG. In hBR96-2C, serine at positions 318, 320, and 322 is encoded by UCU, UCC, UCA, or UGG. In hBR96-2D, alanine at position 331 is encoded by codons GCU, GCC, GCA, or GCG. In hBR96-2E, alanine at positions 235 and 237 is encoded by codons GCU, GCC, GCA, or GCG. Serine at positions 318, 320, and 322 is encoded by UCU, UCC, UCA, or UGG. In hBR96-2F, alanine at positions 235, 237, and 331 is encoded by codons GCU, GCC, GCA, or GCG. In hBR96-2G, serine at positions 318, 320, 322 is encoded by UCU, UCC, UCA, or UGG. Further, the alanine at position 331 is encoded by codons GCU, GCC, GCA, or GCG. In hBR96-2H, alanine at positions 235, 237, and 331 is encoded by codons GCU, GCC, GCA, or GCG. Additionally, serine at positions 318, 320, 322 is encoded by UCU, UCC, UCA, or UGG. Any of the above can be deoxyribonucleic acid (DNA), e.g., complementary DNA (cDNA), or ribonucleic acid (RNA). IMMUNOCONJUGATES Immunoconjugates (having whole antibody or Ig fusion proteins) may be constructed using a wide variety of chemotherapeutic agents such as folic acid and anthracyclines (Peterson et al., "Transport And Storage Of Anthracyclines In Experimental Systems And Human Leukemia", in Anthracycline Antibiotics In Cancer Therapy, Muggia et al. (Eds.), p. 132 (Martinus Nijhoff Publishers (1982); Smyth et al., "Specific Targeting of Chlorambucil to Tumors With the Use of Monoclonal Antibodies", J. Natl. Cancer Inst., 76:503-510 (1986)), including doxorubicin (DOX) (Yang and Reisfeld "Doxorubicin Conjugated with a Monoclonal Antibody Directed to a Human Melanoma-Associated Proteoglycan Suppresses Growth of Established Tumor xenografts in Nude Mice PNAS (USA)" 85:1189-1193 (1988)), Daunomycin (Arnon and Sela "In Vitro and in vivo Efficacy of Conjugates of Daunomycin With Anti-Tumor Antibodies" Immunol. Rev., 65:5- 27 (1982)), and morpholinodoxorubicin (Mueller et al., "Antibody Conjugates With Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem., 1:325- 330 (1990)). BR96 has been conjugated to doxorubicin and has been shown to be effective in therapy of certain cancers or carcinomas (Trail, P.A., Willner, D., Lasch, S.J., Henderson, A.J., Casazza, A.M., Firestone, R.A., Hellstrόm, I., and Hellstrόm, K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science, 261 :212-215, 1993). In accordance with the practice of the invention, structurally altered BR96 can be used in forms including unreduced IgG, reduced structurally altered IgG, and fusion proteins (PCT Application No. 95/305444, published March 6, 1996). Suitable therapeutic agents for use in making the immunoconjugate includes Pseudomonas exotoxin A (PE) in either the native PE or LysPE40 form. LysPE40 is a truncated form containing a genetically modified amino terminus that includes a lysine residue for conjugation purposes. Doxorubicin is also a suitable therapeutic agent. Additional examples of therapeutic agents include, but are not limited to, antimetabolites, alkylating agents, anthracyclines, antibiotics, and anti-mitotic agents. Antimetabolites include methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine. Alkylating agents include mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin. Anthracyclines include daunorubicin (formerly daunomycin) and doxorubicin (also referred to herein as adriamycin). Additional examples include mitozantrone and bisantrene. Antibiotics include dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC). Antimitotic agents include vincristine and vinblastine (which are commonly referred to as vinca alkaloids). Other cytotoxic agents include procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (O,P'-(DDD)), interferons. Further examples of cytotoxic agents include, but are not limited to, ricin, bryodin, gelonin, supporin, doxorubicin, taxol, cytochalasin B, gramicidin D, ethidium bromide, etoposide, tenoposide, colchicine, dihydroxy anthracin dione, 1- dehydrotestosterone, and glucocorticoid. Clearly analogs and homologs of such therapeutic and cytotoxic agents are encompassed by the present invention. For example, the chemotherapuetic agent aminopterin has a correlative improved analog namely methotrexate. Further, the improved analog of doxorubicin is an Fe-chelate. Also, the improved analog for 1-methylnitrosourea is lomustine. Further, the improved analog of vinblastine is vincristine. Also, the improved analog of mechlorethamine is cyclophosphamide. METHODS FOR MAKING MOLECULES OF THE INVENTION There are multiple approaches to making site specific mutations in the CH 2 domain of an immunoglobulin molecule. One approach entails PCR amplification of the CH 2 domain with the mutations followed by homologous recombination of the mutated CH 2 into the vector containing the desired immunoglobulin, e.g., hBR96-2. For example, hBR96-2B and hBR96-2D have been made by this method. Another approach would be to introduce mutations by site-directed mutagenesis of single-stranded DNA. For example, vector pD17-hGlb, which contains only the constant region of IgGl and not the V domain of hBR96, has the fl origin of replication. This gives the vector the properties of a phagemid and site-directed mutagenesis experiments can be performed according to the methods of Kunkel, et al. (Kunkel, T.A., J.D. Roberts, and R.A. Zakour, 1987 Methods Enzymol. 154:367- 383) as provided in the Bio-Rad Muta-Gene® phagemid in vitro mutagenesis kit, version 2. For example, hBR96-2B, -C, -D, -E, -F, -G, and -H were made by this method. In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting the scope of this invention in any manner. EXAMPLE 1 The following standard ELISA protocol was used. Materials: Immulon2 96 well plates and Genetic Systems Specimen Diluent Concentrate (lOx); antibody conjugate was Goat Anti Human Kappa-HRP Mouse Adsorbed, Southern Biotech, at 1:10,000 in Genetic Systems Conjugate Diluent (lx); Genetic Systems EIA Chromogen Reagent (TMB) (1 :100); Genetic Systems EIA Buffered Substrate (lx); primary antibody or antigen were AffiniPure F(ab') 2 Fragment Goat Anti Human IgG Fc Fragment specific (Jackson Immuno Research), Goat Anti Human Kappa-UNLB (Southern Biotechnology Associates), Le y -HSA (Alberta Research Council). Methods: Dilute primary antibody or antigen to 1.0 μg/ml in 0.05M Carb Bicarb buffer. Add lOOμl of the diluted solution per well in Immulon 2 plates. Seal plates and incubate O.N. at 4°C. Block plates by flicking them and blotting on paper towels. Add 200μl/well of Genetic Systems, Specimen Diluent Concentrate (lx). Incubate at least 1 hour at room temperature and then dump the contents of the plates. Wash the plates 3x in saline/Tween. Blot to dry. Allow the plates to dry at R.T. (45 min. to 1 hour). Seal and store the plates at 4°C. Test samples as follows. Dilute samples and standards in Specimen Diluent at 1 : 10. Perform serial dilutions in separate round bottom plates. Transfer lOOμl/well of final dilutions to antigen coated assay plates; then incubate O.N. at 4°C. Wash plates 3x with saline/Tween. For conjugation add 100 μl/well of antibody-HRP conjugate in Genetic Systems Conjugate Diluent (lx). Incubate plates at Room Temp, for 60 min. Wash plates 3x in saline/Tween. Add 100 μl/well of Genetic Systems EIA Chromogen Reagent (TMB) 1 : 100 in EIA Buffered Substrate (lx). Incubate at R.T. for 15 min. and stop with IN H 2 SO 4 100 μl/well. Read plate at 450/630nm in EIA plate reader. EXAMPLE 2 Construction of CH 2 deleted BR96 molecules Strategy for Deleting CH 2 Domains: To construct CH 2 deleted BR96 molecules, the hinge, CH 2 and CH 3 domains were removed from chimeric BR96 and humanized BR9696-2 IgGl molecules by an Eco47-III restriction digestion in non-coding regions. The hinge and CH 3 domains were amplified by polymerase chain reaction (PCR) from a human IgGl (pNγl .14) molecule lacking the CH 2 domain. Two oligonucleotides (Sense 49mer, Antisense 50mer) homologous to the sequences of IgGl constant region at both sides preserving E.co47-III sites were synthesized. The amplified hinge and CH 3 domain PCR fragments were added into Eco47-III sites on BR96 IgGl molecules by in vivo homologous recombination (P. Bubeck et al., Nucleic Acid Research (1993) 21 :3601-3602). The new BR96 IgGl molecules were verified by restriction mapping and sequencing. A sewing PCR strategy was used for the construction of CH 2 deleted human IgGl (pNγl .14) (Robert M. Horton, et al. (1990) Biotech 8 (5)P, 528). The CH ] domain was amplified as a 580 bp fragment with a sense oligonucleotide (5 ' TGG CAC CGA AAG CTT TCT GGG GCA GGC CAG GCC TGA 3 ') (primer A) and an antisense oligonucleotide (5' TCC GAG CAT GTT GGT ACC CAC GTG GTG GTC GAC GCT GAG CCT GGC TTC GAG CAG ACA 3') (primer B) from a linearized human IgGl constant region vector (pNγl .7). The PCR fragment extends from the 5' end of the Hind-III site (in bold) through the Cel-II, Sal-I, Dra- III, Kpn-I, 6 bp nucleotide spacer and Mro-I sites (in bold) at the 3' end of the CH ! domain. The CH 3 domain was then partially amplified (to the Xba-I site) with a sense primer (5' GTC GAC CAC CAC GTG GGT ACC AAC ATG TCC GGA GCC ACA TGG ACA GAG GCC GGC T 3') (primer C) and an antisense primer (5' CTG GTT CTT GTT CAT CTC CTC TCT AGA TGG 3') (primer D) from a linearized human IgGl constant region vector (pNγl .7). A PCR fragment (about 150 bp) with Sal-I, Dra-III, Kpn-I, 6 nucleotide spacer and Mro-I sites (in bold) on its 5' end, extends only through the Xba-1 site (in bold) within the CH 3 domain. The CH] and CH 3 partial PCR fragments were combined in a PCR without any primer. The reaction was run through two full cycles of denaturation and re- annealing to allow the fragments to combine at the homologous region at the 3' ends. Primers A and D (described above) were added to the reaction and the PCR cycle was completed. The polymerase extends the DNA with primer A and primer D, yielding a full- length (660 bp) PCR fragment. The newly extended PCR fragment is arranged from the 5' end to the 3' end in the following order: Hind-III - CH] - Cel-II - Sal-I - Dra-III - Kpn-I - 6 bp spacer - Mro-I - CH 3 partial - Xba-1. The combined PCR fragment, with the CH] and partial CH 3 domains, was then cloned by a blunt end ligation into a Sma-I site on a pEMBLl 8 vector and the sequence was confirmed by dideoxy sequencing (Sanger et al. (1977) PNAS (USA) 74:5463-5466). To transfer the CH] and partial CH 3 into a mammalian expression vector, both the pEMBL18 and pNγl .7 vectors were digested with Hind-III and Xba-I. The Hind-III and Xba-I fragment was ligated into the same sites on a linearized pNγl .7 vector. The new construct, with CH, and a full CH 3 domain, was designated the pNγl .10 vector. The hinge fragment was amplified from a Hind-III digested pNγl .7 vector with the primers designed to flank the hinge exon with a Sal-I and a Dra-III cloning site at each end. These sites also exist between the CHj and CH 3 domains of the pNγl .10 construct. The sense oligonucleotide (5' ACC ATG GTC GAC CTC AGA CCT GCC AAG AGC CAT ATC 3') with a 6 bp spacer and a Sal-I cloning site (in bold) and the antisense oligonucleotide (5' CAT GGT CAC GTG GTG TGT CCC TGG ATG CAG GCT ACT CTA G 3') with a 6 bp spacer and a Dra-III cloning site (in bold) were used for the amplication of the hinge fragment (250 bp). The hinge region PCR fragment was cloned into a Sma-I site on pEMBL18 by blunt end ligation. Both the pEMBLl 8 with the hinge domain and the pNγl .10 with the CH 2 and CH 3 domains were digested with Sal-1 and Dra-III. The digested hinge fragment was cloned into the Sal- 1 and Dra-III linearized sites on the pNγ 1.10 vector. The new construct, now carrying the CH], hinge and CH 3 domains, was designated pNγ 1.11. To make the final CH 2 deleted human IgGl construct, both the pNγl .11 construct and pNγ 1.11 vector were digested with BamHl and Hindlll. A fragment containing the CH], hinge and CH 3 domains was cloned into the linearized pNγl .11 vector. The new constant region IgGl construct lacks the CH 2 domain and is designated pNγ 1.14 (Figure 11). For digestion of BR96 IgGl with Eco47-III, a restriction fragment with hinge, CH 2 and CH 3 domains was identified on the constant region sequence of BR96 IgGl vector in both chimeric and humanized molecules. The 5' end of this fragment lies inside the intron between CH] and hinge and the 3' end is located inside the CH 3 intron of the BR96 IgGl molecule. The hinge, CH 2 and CH 3 domains (1.368 kb fragment) were removed from BR96 IgGl molecules by Eco47-III restriction digestion. The Eco47-III is a blunt end cutter. The BR96 IgGl DNA digested with this enzyme does not require any pretreatment before cloning. Figure 12 is a diagrammatic representation of the pD17-hBR96-2 vector showing the Eco47-III sites used in cloning. The CH 2 deleted BR96 IgGl was then constructed as follows. The hinge and CH 3 domains were amplified from a CH 2 deleted L6 IgGl (pNγl .14) construct with a sense oligonucleotide (5' CAGGGAGGGAGGGTGTCTGCTGGAAGCCAGGCTCAGCGCTGACCTCAG A 3') homologous to the constant region sequence of IgGl at the 5' end of the Eco47-HI site (in bold) and an antisense oligonucleotide (5'GGAAAGAACCATCACAGTCTCGCAGGGG CCCAGGGCAGCGCTGGGTGCTT 3') homologous to the constant region sequence of IgGl at the 3' end of the Eco47-III site (in bold). The Eco47-III site at the 3' end of the pNγl.14 construct is modified in the cloning process. The Eco47- III site is thus introduced into an antisense primer and used in amplification of the hinge and CH 3 domains. The pDl 7-BR96 IgGl vector was digested with Eco47-IIl and the hinge, CH 2 and CH 3 domains were removed. The linearized pD17-BR96 IgGl vector was mixed with equimolar amounts of hinge and CH 3 PCR fragments. Cotransformation of the PCR fragment with linearized DNA into E.coli DH5a competent cells resulted in a recombinant molecule, mediated by homologous recombination in bacteria. This construct lacks the CH 2 domain of BR96 IgGl molecules, and is designated pDl 7- BR96-dCH2 (Figure 13). 1.9 grams of CH 2 -deleted chimeric BR96 was obtained as raw material from 89L of culture supernatant. EXAMPLE 3 Toxicity, localization and clearance of CH 2 -deleted chimeric BR96 was tested in vivo as follows. Three dogs received 400 mg/m of cBR96-A, the CH 2 deletion mutant of chimeric BR96, and two received chimeric BR96. Both molecules had been mildly reduced and alkylated. This is required to prevent dimerization of the deletion mutant into a tetravalent form. Both control dogs experienced the typical GI toxicity and none of the three receiving the mutant displayed any toxicity. The control dogs and two of the test dogs were sacrificed at 1 hr to obtain duodenal tissue to measure antibody localization. Both control dogs had grossly visible GI pathology, and the test dogs had normal appearing GI tissue. The third dog has continued to show no signs of toxicity. Results: A significant amount of localization of the CH 2 deleted cBR96 (cBR96-A) occurred to the GI tract in dogs treated with 400 mg/m 2 , although the intact chiBR96 localized slightly better. The levels of localization indicate that roughly equivalent amounts of intact and CH 2 deleted cBR96 was delivered to the GI tract in these dogs. Table 5. Localization of cBR96 to GI tissue. Group Animal Specific mean Localization #271 155 cBR96 135 #272 114 #273 126 CBR96-A 89 #274 52 Using the mean level of specific localization, an amount of cBR96-A equivalent to at least 66% of the amount of cBR96 was delivered to the target organ of toxicity, the duodenum. Based on the dose ranging done with cBR96 in dogs (some clinical signs of toxicity seen at doses of 10 mg/m 2 ), even if this difference is real, it could not explain the difference between significant toxicity and no toxicity, evaluation to date indicated that dogs treated with cBR96-A had no toxicity, pending microscopic histopathologic examination. This evaluation was based on analysis of 2 frozen blocks per dog and 2 sections per block. Replicates were quite good. We also ran historical frozen tissues from dogs treated with native cBR96 or F(ab)2/BR96 and the levels of localization for those tissues were 110 and 0, respectively, consistent with our previous data. Assuming that there is no toxicity at marginally higher (2X) doses of cBR96-A, these data indicate that the CH 2 domain is associated with the induction of acute gastroenteropathy, and that the removal of this domain prevents the induction of gastroenteropathy mediated by BR96. This study confirms the results showing that F(ab')2 is not toxic in the dog model and that the toxicity is mediated by the constant region. The CH 2 deletion mutant is a candidate for targeting agents clinically. Because of the very long half-life of chimeric BR96, some decrease in the mutant's half-life should be acceptable. Figure 1 shows the measurement of the clearance of the cBR96-A in high Le expressing dogs. The study used chimeric versus constant region mutant of cBR96- 2. CBR96-2 did clear faster than the chimeric BR96. The localization of cBR96-A to the gastrointestinal epithelium is not significantly affected by this more rapid clearance. More than enough of the cBR96-A localized to have caused toxicity. Discussion: The constant region of chimeric IgG is responsible for the GI toxicity seen in clinical trials, e.g. with chiBR96-dox. The GI toxicity seen in the dog model is very similar to the clinical toxicity. Both in man and dog, administration of the unconjugated antibody mediates an acute GI toxicity characterized by rapid onset of vomiting, often with blood. In man the bleeding is limited to the fundus of the stomach, causing erosion of the superficial mucosa of the stomach. Although the pathology of the wound is limited and resolves, the extreme nature of the nausea and vomiting, unrelieved by anti- emetics, defines it as the dose-limiting toxicity. This toxicity is mediated in man and dog by the antibody molecule alone. At higher doses of the antibody-dox conjugate, additional toxicity is seen in the dog model, probably due to doxorubicin. Although the intact IgG of BR96 causes toxicity in dog and man, the F(ab')2 molecule (divalent and lacking only in the constant region) is not toxic in dogs. This finding has motivated our attempts at high levels, and improves the affinity and specificity of BR96 for tumor antigen. The CH 2 domain is known to mediate complement and FcR binding. It was not known that structural alteration of the CH 2 domain would result in immunoglobulin- induced toxicity inhibition. Toxicology study of hBR96-2B The toxicology study of hBR96-2B in high Lewis Y expressor dogs (n=2) showed that a dose of 400 mg/m did not cause hematemesis nor bloody stools, in contrast to BR96 which consistently causes one or both signs. A dog sacrificed at 24 hrs had normal gross appearance of the GI tract, again in marked contrast to chimeric BR96 which causes hemorrhagic lesions and mucosal erosions. EXAMPLE 4 The polymerase chain reaction (PCR) is a widely used and versatile technique for the amplification and subsequent modification of immunoglobulin genes. The rapidity and accuracy with which antibody genes can be modified in vitro has produced an assortment of novel antibody genes can be modified in vitro has produced an assortment of novel antibodies. For example, PCR methods have been used for engineering antibodies with increased affinity to antigen, for "humanizing" antibodies, and for modulating effector function (Marks, J.D., A.D. Griffiths, M. Malmqvist, T. Clackson, J.M. Bye and G. Winter. 1992. Bypassing immunization: high affinity human antibodies by chain shuffling. Bio/Technology 10:779-783; Rosok, M.J., D.E. Yelton, L.J. Harris, J. Bajorath, K.-E. Hellstrom, I. Hellstrom, G.A. Cruz, K. Kristensson, H. Lin, W.D. Huse and S.M. Glaser. 1996. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J. Biol. Chem. 271:22611-22618; Morgan, A.N., D. Jones, A.M. Nesbitt, L. Chaplin, M.W. Bodmer and S. Emtage. 1995. The N-terminal end of the CH2 domain of chimeric human IgGl anti-HLA-DR is necessary for Clq, FcγRI and FcγRIII binding. Immunology. 86:319-324). As part of a more comprehensive study, we desired to introduce various site specific mutations in the CH 2 constant domain of human IgG]. Six specific amino acid residues distributed throughout the CH2 domain previously identified to play a role in immune effector function were marked as targets for mutagenesis (Morgan, A.N., D. Jones, A.M. Nesbitt, L. Chaplin, M.W. Bodmer and S. Emtage. 1995. The N- terminal end of the CH2 domain of chimeric human IgGl anti-HLA-DR is necessary for Clq, FcγRI and FcγRIII binding. Immunology. 86:319-324; Duncan, A.R. and G. Winter. 1988. The binding site for Clq on IgG. Nature 332:738-740; Tao, M.- H., R.I.F. Smith and S.L. Morrison. 1993. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J.Exp.Med. 178:661-667). five of the six residues were grouped into two clusters-one cluster consisting of two residues, two amino acids apart (Location 1, or LI); and a second cluster consisting of three residues spanning a sequence of five amino acids (L2). The remaining amino acid position (L3) made for the total of six residues. We were interested in constructing a panel of mutant CH 2 domain IgGs consisting of each L mutation by itself as well as in combination with other L mutants (e.g., LI; LI; and L2; LI, L2 and L3; etc.). Various in vitro methods have been described where PCR is used to simultaneously introduce distally located site-specific mutations within a gene sequence (Ho, S.N., H.D. Hunt, R.M. Horton, J.K. Pullen and L.R. Pease. 1989. Site-directed mutagenesis by overlap extension. Gene 77:51-59; Ge, L. and P. Rudolpf. 1996. Simultaneous introduction of multiple mutations using overlap extention PCR. BioTechniques 22:28-30). Alternatively, an in vivo procedure termed recombination PCR (RPCR) has also successfully been used for rapidly and efficiently generating distally located site-specific mutations (Jones, D.H. and S.C. Winistorfer. 1993. Use of polymerase chain reaction for making recombinant constructs, p.241-250. In B.A. White (Ed.), Methods in Molecular Biology, Vol. 15. Humana Press Inc., Totowa, NJ, Jones, D.H. And B.H. Howard. 1991. A rapid method for recombination and site-specific mutagenesis by placing homologous ends on DNA using polymerase chain reaction. BioTechniques 10:62-66). RPCR uses E. Coli 's recombination machinery to generate intact circular recombinant plasmids from a transfected mixture of linear PCR-generated product and linearized vector. In vivo recombination is mediated through the joining of nucleotide sequences designed into the 5' ends of both PCR primers that are homologous to DNA sequences encoded by the vector. In this report we describe an extension of the RPCR procedure for simultaneously introducing complex combinations of mutations into an antibody CH 2 domain. Humanized BR96 variable region heavy and light chain genes, previously cloned and co-expressed as an assembled active Fab fragment in an Ml 3 phage expression vector, provided the starting material (Rosok, M.J., D.E. Yelton, L.J. Harris, J. Bajorath, K.-E. Hellstrom, I. Hellstrom, G.A. Cruz, K. Kristensson, H. Lin, W.D. Huse and S.M. Glaser. 1996. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J. Biol. Chem. 271 :2261 1-22618). The heavy and light chain V genes were amplified by PCR from a single-stranded Ml 3 DNA template and subcloned by in vivo recombination (Jones, D.H. And B.H. Howard. 1991. A rapid method for recombination and site-specific mutagenesis by placing homologous ends on DNA using polymerase chain reaction. BioTechniques 10:62-66) into vectors ρD17-hGla and pD16-hCκ, to form pBR96-hGla and pBR96-hCκ respectively. pD17-hGla and pD16-hC are eukaryotic immunoglobulin expression vectors derived from pcDNA3 (Invitrogen, San Diego, CA). The plasmid pBR96-hGla was further modified by site-directed mutagenesis to introduce two Eco47-III restriction sites flanking the immunoglobulin hinge-CH 2 - CH 3 domains using standard procedures. The recipient vector was then prepared by digesting pBR96-hGla with Eco47-III, isolating the vector backbone by agarose gel electrophoresis followed by extracting the vector DNA from the excised gel slice using the Qiagen Gel Extraction kit (Qiagen, Chatsworth, CA). The strategy for introducing multiple mutations within the immunoglobulin CH 2 gene, shown in Figure 24, relies on the in vivo homologous recombination of several independently amplified PCR products with each other as well as with the pBR96- hG la vector DNA. For introducing mutations at two distal locations two PCR products are synthesized (Figure 24B). One end of each PCR product is for recombining with an homologous end of the linear vector, and the other end, encoding the mutation(s) of interest, is for recombining with the neighboring PCR product. As shown in Figure 24B, additional distally-located mutations can be introduced into a target sequence by increasing the number of PCR products proportionately. The recombination of neighboring PCR products always occurs across the regions containing the desired mutations, therefore the oligonucleotide primers encoding these ends (e.g., Al, A2) contain complementary mutant residues. The mutagenic PCR primers contain at least 15 nucleotides of wild-type sequence flanking each side of the mutant residues for either priming the polymerization reaction or mediating recombination. Two 49-nucleotide long PCR sense and antisense primers (Rs and Ra) contain sequences for recombining with the end regions of the Eco47-III digested pBR96-hG la vector. Each L mutation was amplified in a separate PCR reaction. The reaction conditions were 250 ng intact pBR96-hGla DNA template, 10 ul of IX Pfu buffer (Stratagene, Inc. San Diego, CA), 10 nmol dNTPs, 200ng each of the appropriate PCR primers, 10% dimethysulfoxide (ATCC, Rockville, MD) and 2.5 units cloned Pfu DNA polymerase in a lOOul reaction volume. Samples were first denatured at 95° C for 5 min, cooled to 45°C for 5 min, and extended at 72°C for 1 min followed by 25 cycles of denaturation at 94°C for 45 sec, annealing at 45°C for 45 sec, extension at 72°C for 1 min/kb, followed by a final extension at 72°C for 7 min in a Perkin- Elmer DNA Thermal Cycler (Norwalk, CT). The amplified products were purified from a 1% agarose gel, extracted with Qiagen Gel Extraction kit and the recovered DNA quantitated. 50 ng of each PCR product was mixed with 25 ng of the Eco47- III digested pBR96-hG la vector, transfected into Max competent E. coli DH5α according to the manufacturer's procedure (GIBCO BRL/Life Technologies, Gaithersburg, MD), and the entire transfection reaction plated onto selective LB agar plates containing 100 ug/ml ampicillin. The results of several cloning experiments are summarized in the Table that follows. Typically the transformations produced from 80 to 200 bacterial colonies. Individual colonies were selected and grown overnight in 2 ml liquid cultures for isolation of miniprep plasmid DNA (Qiagen) and analysis by Eco47-III restriction endonuclease mapping. Among 24 independent transformants analyzed from triple homologous recombination events (two PCR products plus vector) 11 clones contained the predicted 1.4 kpb DNA insert. Figure 25 shows a sample diagnostic restriction analysis of DNA prepared from clones derived from quadruple homologous recombination events (three PCR products plus vector). Additional sampling of clones resulting from quadruple recombination yielded a cloning efficiency of 29% (7 clones containing inserts/24 clones sampled). At this point, due to the small sampling sizes, we do not know whether the differences in the cloning efficiencies observed between the triple and quadruple recombination events are meaningful. To evaluate the expression of Le? -binding activity of the CH 2 mutant IgGs, miniprep DNAs from 6 clones derived from the triple recombination reaction and 6 clones derived from the quadruple recombination reaction exhibiting the predicted diagnostic Eco47-III restriction patterns were isolated, mixed with pBR96- hCtc DNA and used to co-transfect COS7 cells. 48 hour spent supernatants from 3 ml cultures were assayed for total IgG production and for Le? binding activity by enzyme-linked immunosorbent assay (EIA) as described (Yelton, D.E., M.J. Rosok, G.A. Cruz, W.L. Cosand, J. Bajorath, I. Hellstom, K.-E. Hellstorm, W.D. Huse and S.M. Glaser. 1995. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J.Immunol. 155:1994-2004). All twelve cultures were found to secrete approximately 2-3 ug/ml Le -reactive IgG. The spectrum of Le? binding activities were all similar to that of native humanized BR96 IgG indicating that the homologously recombined antibodies did not acquire any gross mutations that could affect antigen binding. To confirm that the desired CH 2 mutations had been incorporated, and to evaluate the recombined genes for misincorporated nucleotides, four of the clones producing functional antibody were sequenced using Sequenase Version 2 DNA Sequencing Kit (United States Biochemical). One clone was found to contain a single nucleotide change within the forward PCR primer used for mediating recombination with vector DNA. We are uncertain whether this error occurred during chemical synthesis of the oligonucleotide primer or is a result of misincorporation during the PCR reaction, despite the fact that we used a thermostable polymerase with proofreading activity. A RPCR procedure for homologously recombining up to three separate PCR- generated mutated antibody sequence products into a eukaryotic expression vector for the rapid construction of engineered IgG molecules is described herein. The advantage of this approach is the ability to simultaneously introduce multiple distally-located mutations with PCR products synthesized by a single round of PCR. Recombinant DNAs are produced with a reasonably high cloning efficiency and fidelity of correct nucleotide sequences. The ability to efficiently rejoin several distinct PCR products should permit combinatorial strategies for constructing complexly mutated protein domains as well as broadening the number and location of desired mutations. Analysis of transformants generated by multiple-fragment RPCR. Mutant IgGs PCR HR a events Colonies Cloning Constructed Fragments in Analyzed Efficiency reaction 2 2 triple 24 45% 2 3 quadruple 24 33% a HR-homologous recombination b Cloning efficiency (number of clones containing 1.4kbp insert/total number of colonies EXAMPLE 5 This example provides two methods for introducing site specific mutations into the CH2 domain of human IgGl constant region containing vectors. One method involves PCR amplification of a segment or segments of the constant region, wherein mutations are introduced using appropriately constructed oligonucleotides. The vector receiving the fragment(s) is digested with a restriction enzyme to linearize the vector. PCR amplification primers are designed so that the 5' ends of the PCR fragments can hybridize to the DNA sequence of the vectors. If more than one PCR fragment is amplified, then common sequences to the two fragments are introduced by oligonucleotides. Bacteria are transfected with the PCR fragments and with the digested vector. The fragments and vector can recombine by homologous recombination using the bacteria's recombination machinery. Bacterial colonies are selected and the DNA is analyzed by size and restriction map as a preliminary determination that the vector and fragment(s) recombined correctly. Correct insertion of fragments with the mutations is confirmed by dideoxynucleotide sequence analysis. DNA is then introduced into mammalian cells as described for the CH2 deleted antibody, and the expressed antibody analyzed for binding and functional activity. By way of example, mutations Leu to Ala at residue 235 in CH2 and Gly to Ala at residue 237 were introduced by the procedure disclosed in Example 4. The heavy chain vector used for this procedure was pD17-hGla, similar to pD17-BR96 vector described herein except that humanized V regions (Rosok, M.J., D.E. Yelton, L.J. Harris, J. Bajorath, K-E. Hellstrom, I, Hellstrom, G.A. Cruz, K. Kristensson, H. Lin, W.D. Huse, and S.M. Glaser, 1996. J. Biol. Chem 271 37:22611-22618) with three affinity mutations (HI, H2, and H3 mutations) were substituted. pBR96-hGl a contains two Eco47-III restriction sites flanking the Ig hinge-CH2- CH3 domains. The recipient vector was prepared by (1) digesting pBR96-hGla with Eco47-III, (2) isolating the vector by agarose gel electrophoresis, and (3) extracting the vector DNA from the excised gel slice using the Qiagen Gel Extraction kit (Qiagen, Chatsworth, CA). To introduce mutations at a single location, such as for positions 235 and 237, two PCR products were synthesized. To introduce two distally located mutations, such as for mutant F (also referred to herein as hBR96-2F) with mutations at 235, 237, 331 , requires 3 PCR products. The recombination of neighboring PCR products occurs across the regions containing the desired mutations, therefore the oligonucleotide primers encoding these ends contain complementary mutant residues. The mutagenic PCR primers contain at least 15 nucleotides of wild-type sequence flanking each side of the mutant residues for either priming the polymerization reaction or mediating recombination. Two 49- nucleotide long PCR sense and anti-sense primers containing sequences for recombining with the end regions of the Eco47-III digested pBR96-hGla vector. PCR amplification used 250 ng intact pBR96-hGla DNA template, 10 μl of 10X Pfu buffer (Stratagene, Inc., San Diego, CA), 10 nmol dNTPs, 200 ng each of the appropriate PCR primers, 10% dimethylsulfoxide (ATCC, Rockville, MD) and 2.5 units cloned Pfu DNA polymerase (Stratagen, Inc. San Diego, CA) in 100 μl reaction. Samples were denatured at 95°C for 5 min, annealed at 45°C for 5 min, and extended at 72°C for 1 min followed by 25 cycles of denaturation at 94°C for 45 sec, annealing at 45°C for 45 sec, extension at 72°C for 1 min kb, and a final extension at 72°C for 7 min. The amplified products were purified from a 1% agarose gel, extracted with the Qiagen Gel Extraction kit and quantitated. 50 mg of each PCR product was mixed with 25 ng of the Eco47-IH digested pBR96-hGla vector and transfected in E.coli MAX Efficiency DH5α™ according to the manufacturer's instructions (GIBCO BRL/Life Technologies, Gaithersburg, MD). The entire transfection reaction was plated onto LB agar plated containing 100 μg/ml ampicillin. Bacterial colonies were selected and grown overnight at 37° C in 2 ml liquid cultures. DNA was isolated and analyzed by Eco47-III restriction endonuclease mapping. Clones with the correct size insert were sequenced (Sequenase Version 2, U.S. Biochemical Corp., Cleveland, OH). The second method for introducing site specific mutations into the CH 2 domain of human IgGl involved the method of Kunkel (1987 Methods Enzymology, supra). For this procedure pD17-hGlb DNA with the Fl origin of replication was introduced into electrocompetent E. coli CJ236 dut-ung- (Bio-Rad Laboratories, Hercules, CA) by electroporation according to manufacturer's instructions. PDl 7- hGlb is a vector having a constant region but no variable region. The Fl ori site allows treatment of this vector as a phagemid. Bacteria containing the plasmid were selected by ampicillin resistance. Single stranded uridinylated DNA was prepared using the Muta-Gene Phagemid In Vitro Mutagenesis Version 2 protocol (Bio-Rad). Mutations were introduced by site- directed mutagenesis with the appropriate antisense oligonucleotide. For molecules with mutations at more than one location, mutations were introduced by either of the two methods discussed above. One method would be to (1) prepare one mutant, for example, mutant 2C (also referred to herein as BR96-2C) with the mutations at residues 318, 320, 322, (2) isolate ssDNA, and (3) introduce a second mutation set with the appropriate anti-sense oligonucleotide. The second method would be to anneal two antisense oligonucleotides with the same uridinylated ssDNA and screen for mutants with both sets of changes. Mutant 2H (hBR96-2H) was also prepared by a combination of thse methods. The V region of humanized BR96-2 heavy chain was introduced by the homologous recombination method described above in pD17-hJml4.Hl. The pD17-hJml4.Hl plasmid contains the BR96 humanized variable region with the H1 H2 H3 mutations and the plasmid was used to transfect mutant sequences into mammalian cells. The pD17Glb vector containing the Fc mutation(s) was digested with Nhel for 3 hr at 37° C and the DNA isolated by methods described above. Insertion of the V region into the vector was determined by size and restriction enzyme mapping and confirmed by sequence analysis. Transient expression of whole antibodies was performed by transfection of COS cells. For production of antibody, stable transfections of CHO cells were performed (see description of deleted CH2 mutant). All mutants were purified from CHO culture supernatants by protein A chromatography. The oligonucleotide primers homologous to the vector and used to introduce the constant regions mutations were as follows: Oligonucleotides homologous to vector sequences: Sens(sense)CH2 E47-3-5: CAG GGA GGGAGG GTG TCT GCT GGA AGC CAG GCT CAG CGC TGA CCT CAGA D CH2 E47-3 A (antisense): GGAAAG AAC CAT CAC AGT CTC GCA GGG GCC CAG GGC AGC GCT GGG TGC TT Oligonucleotides to mutate Leu235 to Ala and Gly237 to Ala (underlined sequences show sites of mutation): Antisense CH2 L235-G237/aa: GAA GAG GAA GAC TGA CGG XQΩ CCC CGC GAG TTC AGG TGC TGA GG SensCH2 L235-G237/AA: CCT CAG CAC CTG AAC TCC: QΩ . G GGG £ΔC CGT CAG TCT TCC TCT TC Oligonucleotides to mutate Glu318, Lys320, Lys322 to Ser Antis(antisense)CH2 EKK/SSS-2: CTG GGA GGG CTT TGT TGG AGA CQΩ. ΔGC ACjQ ΔGT A£G_ ACT TGC CAT TCA GCC Oligonucleotides to mutate Pro331 to Ala: Antis CH2 P331/A/3: GAT GGT TTT CTC GAT GGC GGC TGG GAG GGC Sense CH2 P33/A: GCC CTC CCA G££ GCC ATC GAG AAA ACC ATC Alternative antisense oligo to introduce Ala at 331 by site-directed mutation: CH2P331A: GAT GGT TTT CTC GAT ΔQC GGC TGG GAG GGC TTT G Oligonucleotides to mutate Glu318 to Ser, Lys320 to Ser, Lys322 to Ser, and Pro331 to Ala: Antis CH2 EKKP/SSA-6: GAT GGT TTT CTC GAT GGC GGC TGG GAG GGC TTT GTT GGA GAC CGA GCA £QA GTA £QΔ CTT GCC ATT CAG CCA GTC CTG GTG Sense CH2 EKKP/SSA-6: CAC CAG GAC TGG CTG AAT GGC AAG 1£G_ TAC 1£G_ TGC J£Q GTC TCC AAC AAA GCC CTC CCA Q£Q GCC ATC GAG AAA ACC ATC In vitro Assays of the Mutants Results of the CDC demonstrate that mutant hBR96-2B has approximately 10 fold less activity than the control hBR96-l (two affinity mutations, one in H2 and one in H3, refer to previous patent (Figure 20)). The mutants that have the least ability to kill cells in the presence of complement is hBR96-2C with the triple mutations at positions 18, 320, and 322 and the hBR96-2H mutant (least cytotoxic antibodies in the panel) which contains all six mutations at the three different locations. ADCC activity was most affected by the CH2 deleted hBR96-2 molecule (Figure 21). hBR96-2B and -2H lost between 100 and 1000 fold activity to kill in the presence of effector cells. In the ADCC assay the hBR96-2B molecule also lost approximately 10 fold activity (Figure 21). Figures 26-28 provide the amino acid sequences for the heavy chain variable region for both chimeric and humanized BR96 having the HI, H2, and H3 mutations. The amino acid sequence for the light chain variable region is known and methods for generating it are found in PCT Application No. 95/305444. Additionally provided is the amino acid sequence for the IgGl constant region. Mutations in the constant region are marked. SEQUENCE LISTING (1) GENERAL INFORMATION (i) APPLICANT: Bristol-Myers Squibb Co. (ii) TITLE OF THE INVENTION: A METHOD FOR INHIBITING IMMUNOGLOBULIN-INDUCED TOXICITY FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS (iii) NUMBER OF SEQUENCES: 13 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Merchant & Gould (B) STREET: 11150 Santa Monica Blvd., Suite 400 (C) CITY: Los Angeles (D) STATE: CA (E) COUNTRY: USA (F) ZIP: 90025 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette (B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS (D) SOFTWARE: FastSEQ Version 2.0 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: PCT/US97/ . (B) FILING DATE: 01-AUG-1997 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 60/023,033 (B) FILING DATE: 02-AUG-1996 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Adriano, Sarah B (B) REGISTRATION NUMBER: 34,470 (C) REFERENCE/DOCKET NUMBER: 30436.43WOU1 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 310-445-1140 (B) TELEFAX: 310-445-9031 (C) TELEX: (2) INFORMATION FOR SEQ ID NO : 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (li) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: TGGCACCGAA AGCTTTCTGG GGCAGGCCAG GCCTGA 36 (2) INFORMATION FOR SEQ ID NO: 2: (l) SEQUENCE CHARACTERISTICS- (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (li) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: TCCGGACATG TTGGTACCCA CGTGGTGGTC GACGCTGAGC CTGGCTTCGA GCAGACA 57 (2) INFORMATION FOR SEQ ID NO : 3 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 55 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi ) SEQUENCE DESCRIPTION: SEQ ID NO : 3 : GTCGACCACC ACGTGGGTAC CAACATGTCC GGAGCCACAT GGACAGAGGC CGGCT 55 (2) INFORMATION FOR SEQ ID NO : 4 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (n ) MOLECULE TYPE: cDNA (xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 4: CTGGTTCTTG TTCATCTCCT CTCTAGATGG 30 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (il) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ACCATGGTCG ACCTCAGACC TGCCAAGAGC CATATC 36 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : CATGGTCACG TGGTGTGTCC CTGGATGCAG GCTACTCTA 39 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CAGGGAGGGA GGGTGTCTGC TGGAAGCCAG GCTCAGCGCT GACCTCAGA 49 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 50 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: GGAAAGAACC ATCACAGTCT CGCAGGGGCC CAGGGCAGCG CTGGGTGCTT 50 (2) INFORMATION FOR SEQ ID NO : 9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8691 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GACGGATCGG GAGATCTGCT AGGTGACCTG AGGCGCGCCG GCTTCGAATA GCCAGAGTAA 60 CCTTTTTTTT TAATTTTATT TTATTTTATT TTTGAGATGG AGTTTGGCGC CGATCTCCCG 120 ATCCCCTATG GTCGACTCTC AGTACAATCT GCTCTGATGC CGCATAGTTA AGCCAGTATC 180 TGCTCCCTGC TTGTGTGTTG GAGGTCGCTG AGTAGTGCGC GAGCAAAATT TAAGCTACAA 240 CAAGGCAAGG CTTGACCGAC AATTGCATGA AGAATCTGCT TAGGGTTAGG CGTTTTGCGC 300 TGCTTCGCGA TGTACGGGCC AGATATACGC GTTGACATTG ATTATTGACT AGTTATTAAT 360 AGTAATCAAT TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCCGC GTTACATAAC 420 TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG ACGTCAATAA 480 TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA TGGGTGGACT 540 ATTTACGGTA AACTGCCCAC TTGGCAGTAC ATCAAGTGTA TCATATGCCA AGTACGCCCC 600 CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATTA TGCCCAGTAC ATGACCTTAT 660 GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC ATGGTGATGC 720 GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA TTTCCAAGTC 780 TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG GACTTTCCAA 840 AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA CGGTGGGAGG 900 TCTATATAAG CAGAGCTCTC TGGCTAACTA GAGAACCCAC TGCTTACTGG CTTATCGAAA 960 TTAATACGAC TCACTATAGG GAGACCCAAG CTTGGTACCA ATTTAAATTG ATATCTCCTT 1020 AGGTCTCGAG TCTCTAGATA ACCGGTCAAT CGATTGGAAT TCTTGCGGCC GCTTGCTAGC 1080 CACCATGGAG TTGTGGTTAA GCTTGGTCCT TCCTTGTCCT TGTTTTAAAA GGTGTCCAGT 1140 GTGAAGTGAA TCTGGTGGAG TCTGGGGGAG GCTTAGTGCA GCCTGGAGGG TCCCTGAAAG 1200 TCTCCTGTGT AACCTCTGGA TTCACTTTCA GTGACTATTA CATGTATTGG GTTCGCCAGA 1260 CTCCAGAGAA GAGGCTGGAG TGGGTCGCAT ACATTAGTCA AGGTGGTGAT ATAACCGACT 1320 ATCCAGACAC TGTAAAGGGT CGATTCACCA TCTCCAGAGA CAATGCCAAG AACACCCTGT 1380 ACCTGCAAAT GAGCCGTCTG AAGTCTGAGG ACACAGCCAT GTATTACTGT GCAAGAGGCC 1440 TGGACGACGG GGCCTGGTTT GCTTACTGGG GCCAAGGGAC TCTGGTCACG GTCTCTGTAG 1500 CTAGCACCAA GGGCCCATCG GTCTTCCCCC TGGCACCCTC CTCCAAGAGC ACCTCTGGGG 1560 GCACAGCGGC CCTGGGCTGC CTGGTCAAGG ACTACTTCCC CGAACCGGTG ACGGTGTCGT 1620 GGAACTCAGG CGCCCTGACC AGCGGCGTGC ACACCTTCCC GGCTGTCCTA CAGTCCTCAG 1680 GACTCTACTC CCTCAGCAGC GTGGTCACCG TGCCCTCCAG CAGCTTGGGC ACCCAGACCT 1740 ACATCTGCAA CGTGAATCAC AAGCCCAGCA ACACCAAGGT GGACAAGAAA GTTGGTGAGA 1800 GGCCAGCACA GGGAGGGAGG GTGTCTGCTG GAAGCCAGGC TCAGCGCTCC TGCCTGGACG 1860 CATCCCGGCT ATGCAGCCCC AGTCCAGGGC AGCAAGGCAG GCCCCGTCTG CCTCTTCACC 1920 CGGAGGCCTC TGCCCGCCCC ACTCATGCTC AGGGAGAGGG TCTTCTGGCT TTTTCCCCAG 1980 GCTCTGGGCA GGCACAGGCT AGGTGCCCCT AACCCAGGCC CTGCACACAA AGGGGCAGGT 2040 GCTGGGCTCA GACCTGCCAA GAGCCATATC CGGGAGGACC CTGCCCCTGA CCTAAGCCCA 2100 CCCCAAAGGC CAAACTCTCC ACTCCCTCAG CTCGGACACC TTCTCTCCTC CCAGATTCCA 2160 GTAACTCCCA ATCTTCTCTC TGCAGAGCCC AAATCTTGTG ACAAAACTCA CACATGCCCA 2220 CCGTGCCCAG GTAAGCCAGC CCAGGCCTCG CCCTCCAGCT CAAGGCGGGA CAGGTGCCCT 2280 AGAGTAGCCT GCATCCAGGG ACAGGCCCCA GCCGGGTGCT GACACGTCCA CCTCCATCTC 2340 TTCCTCAGCA CCTGAACTCC TGGGGGGACC GTCAGTCTTC CTCTTCCCCC CAAAACCCAA 2400 GGACACCCTC ATGATCTCCC GGACCCCTGA GGTCACATGC GTGGTGGTGG ACGTGAGCCA 2460 CGAAGACCCT GAGGTCAAGT TCAACTGGTA CGTGGACGGC GTGGAGGTGC ATAATGCCAA 2520 GACAAAGCCG CGGGAGGAGC AGTACAACAG CACGTACCGT GTGGTCAGCG TCCTCACCGT 2580 CCTGCACCAG GACTGGCTGA ATGGCAAGGA GTACAAGTGC AAGGTCTCCA ACAAAGCCCT 2640 CCCAGCCCCC ATCGAGAAAA CCATCTCCAA AGCCAAAGGT GGGACCCGTG GGGTGCGAGG 2700 GCCACATGGA CAGAGGCCGG CTCGGCCCAC CCTCTGCCCT GAGAGTGACC GCTGTACCAA 2760 CCTCTGTCCC TACAGGGCAG CCCCGAGAAC CACAGGTGTA CACCCTGCCC CCATCCCGGG 2820 ATGAGCTGAC CAAGAACCAG GTCAGCCTGA CCTGCCTGGT CAAAGGCTTC TATCCCAGCG 2880 ACATCGCCGT GGAGTGGGAG AGCAATGGGC AGCCGGAGAA CAACTACAAG ACCACGCCTC 2940 CCGTGCTGGA CTCCGACGGC TCCTTCTTCC TCTACAGCAA GCTCACCGTG GACAAGAGCA 3000 GGTGGCAGCA GGGGAACGTC TTCTCATGCT CCGTGATGCA TGAGGCTCTG CACAACCACT 3060 ACACGCAGAA GAGCCTCTCC CTGTCTCCGG GTAAATGAGT GCGACGGCCG GCAAGCCCCC 3120 GCTCCCCGGG CTCTCGCGGT CGCACGAGGA TGCTTGGCAC GTACCCCCTG TACATACTTC 3180 CCGGGCGCCC AGCATGGAAA TAAAGCACCC AGCGCTGCCC TGGGCCCCTG CGAGACTGTG 3240 ATGGTTCTTT CCACGGGTCA GGCCGAGTCT GAGGCCTGAG TGGCATGAGG GAGGCAGAGC 3300 GGGTCCCACT GTCCCCACAC TGGCCCAGGC TGTGCAGGTG TGCCTGGGCC CCCTAGGGTG 3360 GGOCTCAGCC AGGGGCTGCC CTCGGCAGGG TGGGGGATTT GCCAGCGTGG CCCTCCCTCC 3420 AGCAGCACCT GCCCTGGGCT GGGCCACGGG AAGCCCTAGG AGCCCCTGGG GACAGACACA 3480 CAGCCCCTGC CTCTGTAGGA GACTGTCCTG TTCTGTGAGC GCCCCTGTCC TCCCGACCTC 3540 CATGCCCACT CGGGGGCATG CCTAGTCCAT GTGCGTAGGG ACAGGCCCTC CCTCACCCAT 3600 CTACCCCCAC GGCACTAACC CCTGGCTGCC CTGCCCAGCC TCGCACCCGC ATGGGGACAC 3660 AACCGACTCC GGGGACATGC ACTCTCGGGC CCTGTGGAGG GACTGGTGCA GATGCCCACA 3720 CACACACTCA GCCCAGACCC GTTCAACAAA CCCCGCACTG AGGTTGGCCG GCCACACGGC 3780 CACCACACAC ACACGTGCAC GCCTCACACA CGGAGCCTCA CCCGGGCGAA CTGCACAGCA 3840 CCCAGACCAG AGCAAGGTCC TCGCACACGT GAACACTCCT CGGACACAGG CCCCCACGAG 3900 CCCCACGCGG CACCTCAAGG CCCACGAGCC TCTCGGCAGC TTCTCCACAT GCTGACCTGC 3960 TCAGACAAAC CCAGCCCTCC TCTCACAAGG GTGCCCCTGC AGCCGCCACA CACACACAGG 4020 GGATCACACA CCACGTCACG TCCCTGGCCC TGGCCCACTT CCCAGTGCCG CCCTTCCCTG 4080 CAGGACGGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC CATCTGTTGT TTGCCCCTCC 4140 CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCACTG TCCTTTCCTA ATAAAATGAG 4200 GAAATTGCAT CGCATTGTCT GAGTAGGTGT CATTCTATTC TGGGGGGTGG GGTGGGGCAG 4260 GACAGCAAGG GGGAGGATTG GGAAGACAAT AGCAGGCATG CTGGGGATGC GGTGGGCTCT 4320 ATGGCTTCTG AGGCGGAAAG AACCAGCTGG GGCTCTAGGG GGTATCCCCA CGCGCCCTGT 4380 AGCGGCGCAT TAAGCGCGGC GGGTGTGGTG GTTACGCGCA GCGTGACCGC TACACTTGCC 4440 AGCGCCCTAG CGCCCGCTCC TTTCGCTTTC TTCCCTTCCT TTCTCGCCAC GTTCGCCGGG 4500 CCTCTCAAAA AAGGGAAAAA AAGCATGCAT CTCAATTAGT CAGCAACCAT AGTCCCGCCC 4560 CTAACTCCGC CCATCCCGCC CCTAACTCCG CCCAGTTCCG CCCATTCTCC GCCCCATGGC 4620 TGACTAATTT TTTTTATTTA TGCAGAGGCC GAGGCCGCCT CGGCCTCTGA GCTATTCCAG 4680 AAGTAGTGAG GAGGCTTTTT TGGAGGCCTA GGCTTTTGCA AAAAGCTTGG ACAGCTCAGG 4740 GCTGCGATTT CGCGCCAAAC TTGACGGCAA TCCTAGCGTG AAGGCTGGTA GGATTTTATC 4800 CCCGCTGCCA TCATGGTTCG ACCATTGAAC TGCATCGTCG CCGTGTCCCA AAATATGGGG 4860 ATTGGCAAGA ACGGAGACCT ACCCTGGCCT CCGCTCAGGA ACGAGTTCAA GTACTTCCAA 4920 AGAATGACCA CAACCTCTTC AGTGGAAGGT AAACAGAATC TGGTGATTAT GGGTAGGAAA 4980 ACCTGGTTCT CCATTCCTGA GAAGAATCGA CCTTTAAAGG ACAGAATTAA TATAGTTCTC 5040 AGTAGAGAAC TCAAAGAACC ACCACGAGGA GCTCATTTTC TTGCCAAAAG TTTGGATGAT 5100 GCCTTAAGAC TTATTGAACA ACCGGAATTG GCAAGTAAAG TAGACATGGT TTGGATAGTC 5160 GGAGGCAGTT CTGTTTACCA GGAAGCCATG AATCAACCAG GCCACCTTAG ACTCTTTGTG 5220 ACAAGGATCA TGCAGGAATT TGAAAGTGAC ACGTTTTTCC CAGAAATTGA TTTGGGGAAA 5280 TATAAACTTC TCCCAGAATA CCCAGGCGTC CTCTCTGAGG TCCAGGAGGA AAAAGGCATC 5340 AAGTATAAGT TTGAAGTCTA CGAGAAGAAA GACTAACAGG AAGATGCTTT CAAGTTCTCT 5400 GCTCCCCTCC TAAAGCTATG CATTTTTATA AGACCATGGG ACTTTTGCTG GCTTTAGATC 5460 TCTTTGTGAA GGAACCTTAC TTCTGTGGTG TGACATAATT GGACAAACTA CCTACAGAGA 5520 TTTAAAGCTC TAAGGTAAAT ATAAAATTTT TAAGTGTATA ATGTGTTAAA CTACTGATTC 5580 TAATTGTTTG TGTATTTTAG ATTCCAACCT ATGGAACTGA TGAATGGGAG CAGTGGTGGA 5640 ATGCCTTTAA TGAGGAAAAC CTGTTTTGCT CAGAAGAAAT GCCATCTAGT GATGATGAGG 5700 CTACTGCTGA CTCTCAACAT TCTACTCCTC CAAAAAAGAA GAGAAAGGTA GAAGACCCCA 5760 AGGACTTTCC TTCAGAATTG CTAAGTTTTT TGAGTCATGC TGTGTTTAGT AATAGAACTC 5820 TTGCTTGCTT TGCTATTTAC ACCACAAAGG AAAAAGCTGC ACTGCTATAC AAGAAAATTA 5880 TGGAAAAATA TTCTGTAACC TTTATAAGTA GGCATAACAG TTATAATCAT AACATACTGT 5940 TTTTTCTTAC TCCACACAGG CATAGAGTGT CTGCTATTAA TAACTATGCT CAAAAATTGT 6000 GTACCTTTAG CTTTTTAATT TGTAAAGGGG TTAATAAGGA ATATTTGATG TATAGTGCCT 6060 TGACTAGAGA TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAAC 6120 CTCCCACACC TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTTAACTTG 6180 TTTATTGCAG CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA 6240 GCATTTTTTT CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT 6300 GTCTGGATCG GCTGGATGAT CCTCCAGCGC GGGGATCTCA TGCTGGAGTT CTTCGCCCAC 6360 CCCAACTTGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTTC 6420 ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA 6480 TCTTATCATG TCTGTATACC GTCGACCTCT AGCTAGAGCT TGGCGTAATC ATGGTCATAG 6540 CTGTTTCCTG TGTGAAATTG TTATCCGCTC ACAATTCCAC ACAACATACG AGCCGGAAGC 6600 ATAAAGTGTA AAGCCTGGGG TGCCTAATGA GTGAGCTAAC TCACATTAAT TGCGTTGCGC 6660 TCACTGCCCG CTTTCCAGTC GGGAAACCTG TCGTGCCAGC TGCATTAATG AATCGGCCAA 6720 CGCGCGGGGA GAGGCGGTTT GCGTATTGGG CGCTCTTCCG CTTCCTCGCT CACTGACTCG 6780 CTGCGCTCGG TCGTTCGGCT GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG 6840 TTATCCACAG AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG 6900 GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC 6960 GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA 7020 TACCAGGCGT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT 7080 ACCGGATACC TGTCCGCCTT TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA ATGCTCACGC 7140 TGTAGGTATC TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC 7200 CCCGTTCAGC CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA 7260 AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT 7320 GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT ACGGCTACAC TAGAAGGACA 7380 GTATTTGGTA TCTGCGCTCT GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT 7440 TGATCCGGCA AACAAACCAC CGCTGGTAGC GGTGGTTTTT TTGTTTGCAA GCAGCAGATT 7500 ACGCGCAGAA AAAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT 7560 CAGTGGAACG AAAACTCACG TTAAGGGATT TTGGTCATGA GATTATCAAA AAGGATCTTC 7620 ACCTAGATCC TTTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT ATATGAGTAA 7680 ACTTGGTCTG ACAGTTACCA ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA 7740 TTTCGTTCAT CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC 7800 TTACCATCTG GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT 7860 TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA 7920 TCCGCCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT 7980 AATAGTTTGC GCAACGTTGT TGCCATTGCT ACAGGCATCG TGGTGTCACG CTCGTCGTTT 8040 GGTATGGCTT CATTCAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG 8100 TTGTGCAAAA AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC 8160 GCAGTGTTAT CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC 8220 GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGTATG 8280 CGGCGACCGA GTTGCTCTTG CCCGGCGTCA ATACGGGATA ATACCGCGCC ACATAGCAGA 8340 ACTTTAAAAG TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACTCTC AAGGATCTTA 8400 CCGCTGTTGA GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT 8460 TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG 8520 GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTTCA ATATTATTGA 8580 AGCATTTATC AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT 8640 AAACAAATAG GGGTTCCGCG CACATTTCCC CGAAAAGTGC CACCTGACGT C 8691 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8327 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: GACGGATCGG GAGATCTGCT AGGTGACCTG AGGCGCGCCG GCTTCGAATA GCCAGAGTAA 60 CCTTTTTTTT TAATTTTATT TTATTTTATT TTTGAGATGG AGTTTGGCGC CGATCTCCCG 120 ATCCCCTATG GTCGACTCTC AGTACAATCT GCTCTGATGC CGCATAGTTA AGCCAGTATC 180 TGCTCCCTGC TTGTGTGTTG GAGGTCGCTG AGTAGTGCGC GAGCAAAATT TAAGCTACAA 240 CAAGGCAAGG CTTGACCGAC AATTGCATGA AGAATCTGCT TAGGGTTAGG CGTTTTGCGC 300 TGCTTCGCGA TGTACGGGCC AGATATACGC GTTGACATTG ATTATTGACT AGTTATTAAT 360 AGTAATCAAT TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCCGC GTTACATAAC 420 TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG ACGTCAATAA 480 TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA TGGGTGGACT 540 ATTTACGGTA AACTGCCCAC TTGGCAGTAC ATCAAGTGTA TCATATGCCA AGTACGCCCC 600 CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATTA TGCCCAGTAC ATGACCTTAT 660 GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC ATGGTGATGC 720 GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA TTTCCAAGTC 780 TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG GACTTTCCAA 8 0 AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCGTGTA CGGTGGGAGG 900 TCTATATAAG CAGAGCTCTC TGGCTAACTA GAGAACCCAC TGCTTACTGG CTTATCGAAA 960 TTAATACGAC TCACTATAGG GAGACCCAAG CTTGGTACCA ATTTAAATTG ATATCTCCTT 1020 AGGTCTCGAG TCTCTAGATA ACCGGTCAAT CGATTGGAAT TCTTGCGGCC GCTTGCTAGC 1080 CACCATGGAG TTGTGGTTAA GCTTGGTCCT TCCTTGTCCT TGTTTTAAAA GGTGTCCAGT 1140 GTGAAGTGAA TCTGGTGGAG TCTGGGGGAG GCTTAGTGCA GCCTGGAGGG TCCCTGAAAG 1200 TCTCCTGTGT AACCTCTGGA TTCACTTTCA GTGACTATTA CATGTATTGG GTTCGCCAGA 1260 CTCCAGAGAA GAGGCTGGAG TGGGTCGCAT ACATTAGTCA AGGTGGTGAT ATAACCGACT 1320 ATCCAGACAC TGTAAAGGGT CGATTCACCA TCTCCAGAGA CAATGCCAAG AACACCCTGT 1380 ACCTGCAAAT GAGCCGTCTG AAGTCTGAGG ACACAGCCAT GTATTACTGT GCAAGAGGCC 1440 TGGACGACGG GGCCTGGTTT GCTTACTGGG GCCAAGGGAC TCTGGTCACG GTCTCTGTAG 1500 CTAGCACCAA GGGCCCATCG GTCTTCCCCC TGGCACCCTC CTCCAAGAGC ACCTCTGGGG 1560 GCACAGCGGC CCTGGGCTGC CTGGTCAAGG ACTACTTCCC CGAACCGGTG ACGGTGTCGT 1620 GGAACTCAGG CGCCCTGACC AGCGGCGTGC ACACCTTCCC GGCTGTCCTA CAGTCCTCAG 1680 GACTCTACTC CCTCAGCAGC GTGGTCACCG TGCCCTCCAG CAGCTTGGGC ACCCAGACCT 1740 ACATCTGCAA CGTGAATCAC AAGCCCAGCA ACACCAAGGT GGACAAGAAA GTTGGTGAGA 1800 GGCCAGCACA GGGAGGGAGG GTGTCTGCTG GAAGCCAGGC TCAGCGCTCC TGCCTGGACG 1860 CATCCCGGCT ATGCAGCCCC AGTCCAGGGC AGCAAGGCAG GCCCCGTCTG CCTCTTCACC 1920 CGGAGGCCTC TGCCCGCCCC ACTCATGCTC AGGGAGAGGG TCTTCTGGCT TTTTCCCCAG 1980 GCTCTGGGCA GGCACAGGCT AGGTGCCCCT AACCCAGGCC CTGCACACAA AGGGGCAGGT 2040 GCTGGGCTCA GACCTGCCAA GAGCCATATC CGGGAGGACC CTGCCCCTGA CCTAAGCCCA 2100 CCCCAAAGGC CAAACTCTCC ACTCCCTCAG CTCGGACACC TTCTCTCCTC CCAGATTCCA 2160 GTAACTCCCA ATCTTCTCTC TGCAGAGCCC AAATCTTGTG ACAAAACTCA CACATGCCCA 2220 CCGTGCCCAG GTAAGCCAGC CCAGGCCTCG CCCTCCAGCT CAAGGCGGGA CAGGTGCCCT 2280 AGAGTAGCCT GCATCCAGGG ACACACCACG TGGGTACCAA CATGTCCGGA GCCACATGGA 2340 CAGAGGCCGG CTCGGCCCAC CCTCTGCCCT GAGAGTGACC GCTGTACCAA CCTCTGTCCC 2400 TACAGGGCAG CCCCGAGAAC CACAGGTGTA CACCCTGCCC CCATCCCGGG ATGAGCTGAC 2460 CAAGAACCAG GTCAGCCTGA CCTGCCTGGT CAAAGGCTTC TATCCCAGCG ACATCGCCGT 2520 GGAGTGGGAG AGCAATGGGC AGCCGGAGAA CAACTACAAG ACCACGCCTC CCGTGCTGGA 2580 CTCCGACGGC TCCTTCTTCC TCTACAGCAA GCTCACCGTG GACAAGAGCA GGTGGCAGCA 2640 GGGGAACGTC TTCTCATGCT CCGTGATGCA TGAGGCTCTG CACAACCACT ACACGCAGAA 2700 GAGCCTCTCC CTGTCTCCGG GTAAATGAGT GCGACGGCCG GCAAGCCCCC GCTCCCCGGG 2760 CTCTCGCGGT CGCACGAGGA TGCTTGGCAC GTACCCCCTG TACATACTTC CCGGGCGCCC 2820 AGCATGGAAA TAAAGCACCC AGCGCTGCCC TGGGCCCCTG CGAGACTGTG ATGGTTCTTT 2880 CCACGGGTCA GGCCGAGTCT GAGGCCTGAG TGGCATGAGG GAGGCAGAGC GGGTCCCACT 2940 GTCCCCACAC TGGCCCAGGC TGTGCAGGTG TGCCTGGGCC CCCTAGGGTG GGGCTCAGCC 3000 AGOGGCTGCC CTCGGCAGGG TGGGGGATTT GCCAGCGTGG CCCTCCCTCC AGCAGCACCT 3060 GCCCTGGGCT GGGCCACGGG AAGCCCTAGG AGCCCCTGGG GACAGACACA CAGCCCCTGC 3120 CTCTGTAGGA GACTGTCCTG TTCTGTGAGC GCCCCTGTCC TCCCGACCTC CATGCCCACT 3180 CGGGGGCATG CCTAGTCCAT GTGCGTAGGG ACAGGCCCTC CCTCACCCAT CTACCCCCAC 3240 GGCACTAACC CCTGGCTGCC CTGCCCAGCC TCGCACCCGC ATGGGGACAC AACCGACTCC 3300 GGGGACATGC ACTCTCGGGC CCTGTGGAGG GACTGGTGCA GATGCCCACA CACACACTCA 3360 GCCCAGACCC GTTCAACAAA CCCCGCACTG AGGTTGGCCG GCCACACGGC CACCACACAC 3420 ACACGTGCAC GCCTCACACA CGGAGCCTCA CCCGGGCGAA CTGCACAGCA CCCAGACCAG 3480 AGCAAGGTCC TCGCACACGT GAACACTCCT CGGACACAGG CCCCCACGAG CCCCACGCGG 3540 CACCTCAAGG CCCACGAGCC TCTCGGCAGC TTCTCCACAT GCTGACCTGC TCAGACAAAC 3600 CCAGCCCTCC TCTCACAAGG GTGCCCCTGC AGCCGCCACA CACACACAGG GGATCACACA 3660 CCACGTCACG TCCCTGGCCC TGGCCCACTT CCCAGTGCCG CCCTTCCCTG CAGGACGGAT 3720 CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC CATCTGTTGT TTGCCCCTCC CCCGTGCCTT 3780 CCTTGACCCT GGAAGGTGCC ACTCCCACTG TCCTTTCCTA ATAAAATGAG GAAATTGCAT 3840 CGCATTGTCT GAGTAGGTGT CATTCTATTC TGGGGGGTGG GGTGGGGCAG GACAGCAAGG 3900 GGGAGGATTG GGAAGACAAT AGCAGGCATG CTGGGGATGC GGTGGGCTCT ATGGCTTCTG 3960 AGGCGGAAAG AACCAGCTGG GGCTCTAGGG GGTATCCCCA CGCGCCCTGT AGCGGCGCAT 4020 TAAGCGCGGC GGGTGTGGTG GTTACGCGCA GCGTGACCGC TACACTTGCC AGCGCCCTAG 4080 CGCCCGCTCC TTTCGCTTTC TTCCCTTCCT TTCTCGCCAC GTTCGCCGGG CCTCTCAAAA 4140 AAGGGAAAAA AAGCATGCAT CTCAATTAGT CAGCAACCAT AGTCCCGCCC CTAACTCCGC 4200 CCATCCCGCC CCTAACTCCG CCCAGTTCCG CCCATTCTCC GCCCCATGGC TGACTAATTT 4260 TTTTTATTTA TGCAGAGGCC GAGGCCGCCT CGGCCTCTGA GCTATTCCAG AAGTAGTGAG 4320 GAGGCTTTTT TGGAGGCCTA GGCTTTTGCA AAAAGCTTGG ACAGCTCAGG GCTGCGATTT 4380 CGCGCCAAAC TTGACGGCAA TCCTAGCGTG AAGGCTGGTA GGATTTTATC CCCGCTGCCA 4440 TCATGGTTCG ACCATTGAAC TGCATCGTCG CCGTGTCCCA AAATATGGGG ATTGGCAAGA 4500 ACGGAGACCT ACCCTGGCCT CCGCTCAGGA ACGAGTTCAA GTACTTCCAA AGAATGACCA 4560 CAACCTCTTC AGTGGAAGGT AAACAGAATC TGGTGATTAT GGGTAGGAAA ACCTGGTTCT 4620 CCATTCCTGA GAAGAATCGA CCTTTAAAGG ACAGAATTAA TATAGTTCTC AGTAGAGAAC 4680 TCAAAGAACC ACCACGAGGA GCTCATTTTC TTGCCAAAAG TTTGGATGAT GCCTTAAGAC 4740 TTATTGAACA ACCGGAATTG GCAAGTAAAG TAGACATGGT TTGGATAGTC GGAGGCAGTT 4800 CTGTTTACCA GGAAGCCATG AATCAACCAG GCCACCTTAG ACTCTTTGTG ACAAGGATCA 4860 TGCAGGAATT TGAAAGTGAC ACGTTTTTCC CAGAAATTGA TTTGGGGAAA TATAAACTTC 4920 TCCCAGAATA CCCAGGCGTC CTCTCTGAGG TCCAGGAGGA AAAAGGCATC AAGTATAAGT 4980 TTGAAGTCTA CGAGAAGAAA GACTAACAGG AAGATGCTTT CAAGTTCTCT GCTCCCCTCC 5040 TAAAGCTATG CATTTTTATA AGACCATGGG ACTTTTGCTG GCTTTAGATC TCTTTGTGAA 5100 GGAACCTTAC TTCTGTGGTG TGACATAATT GGACAAACTA CCTACAGAGA TTTAAAGCTC 5160 TAAGGTAAAT ATAAAATTTT TAAGTGTATA ATGTGTTAAA CTACTGATTC TAATTGTTTG 5220 TGTATTTTAG ATTCCAACCT ATGGAACTGA TGAATGGGAG CAGTGGTGGA ATGCCTTTAA 5280 TGAGGAAAAC CTGTTTTGCT CAGAAGAAAT GCCATCTAGT GATGATGAGG CTACTGCTGA 5340 CTCTCAACAT TCTACTCCTC CAAAAAAGAA GAGAAAGGTA GAAGACCCCA AGGACTTTCC 5400 TTCAGAATTG CTAAGTTTTT TGAGTCATGC TGTGTTTAGT AATAGAACTC TTGCTTGCTT 5460 TGCTATTTAC ACCACAAAGG AAAAAGCTGC ACTGCTATAC AAGAAAATTA TGGAAAAATA 5520 TTCTGTAACC TTTATAAGTA GGCATAACAG TTATAATCAT AACATACTGT TTTTTCTTAC 5580 TCCACACAGG CATAGAGTGT CTGCTATTAA TAACTATGCT CAAAAATTGT GTACCTTTAG 5640 CTTTTTAATT TGTAAAGGGG TTAATAAGGA ATATTTGATG TATAGTGCCT TGACTAGAGA 5700 TCATAATCAG CCATACCACA TTTGTAGAGG TTTTACTTGC TTTAAAAAAC CTCCCACACC 5760 TCCCCCTGAA CCTGAAACAT AAAATGAATG CAATTGTTGT TGTTAACTTG TTTATTGCAG 5820 CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT CACAAATAAA GCATTTTTTT 5880 CACTGCATTC TAGTTGTGGT TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGATCG 5940 GCTGGATGAT CCTCCAGCGC GGGGATCTCA TGCTGGAGTT CTTCGCCCAC CCCAACTTGT 6000 TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTTC ACAAATAAAG 6060 CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA TCTTATCATG 6120 TCTGTATACC GTCGACCTCT AGCTAGAGCT TGGCGTAATC ATGGTCATAG CTGTTTCCTG 6180 TGTGAAATTG TTATCCGCTC ACAATTCCAC ACAACATACG AGCCGGAAGC ATAAAGTGTA 6240 AAGCCTGGGG TGCCTAATGA GTGAGCTAAC TCACATTAAT TGCGTTGCGC TCACTGCCCG 6300 CTTTCCAGTC GGGAAACCTG TCGTGCCAGC TGCATTAATG AATCGGCCAA CGCGCGGGGA 6360 GAGGCGGTTT GCGTATTGGG CGCTCTTCCG CTTCCTCGCT CACTGACTCG CTGCGCTCGG 6420 TCGTTCGGCT GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG TTATCCACAG 6480 AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG GCCAGGAACC 6540 GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC GAGCATCACA 6600 AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA TACCAGGCGT 6660 TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT ACCGGATACC 6720 TGTCCGCCTT TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA ATGCTCACGC TGTAGGTATC 6780 TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC CCCGTTCAGC 6840 CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA AGACACGACT 6900 TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT GTAGGCGGTG 6960 CTACAGAGTT CTTGAAGTGG TGGCCTAACT ACGGCTACAC TAGAAGGACA GTATTTGGTA 7020 TCTGCGCTCT GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT TGATCCGGCA 7080 AACAAACCAC CGCTGGTAGC GGTGGTTTTT TTGTTTGCAA GCAGCAGATT ACGCGCAGAA 7140 AAAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT CAGTGGAACG 7200 AAAACTCACG TTAAGGGATT TTGGTCATGA GATTATCAAA AAGGATCTTC ACCTAGATCC 7260 TTTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT ATATGAGTAA ACTTGGTCTG 73 0 ACAGTTACCA ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA TTTCGTTCAT 7380 CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC TTACCATCTG 7440 GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT TTATCAGCAA 7500 TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA TCCGCCTCCA 7560 TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT AATAGTTTGC 7620 GCAACGTTGT TGCCATTGCT ACAGGCATCG TGGTGTCACG CTCGTCGTTT GGTATGGCTT 7680 CATTCAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG TTGTGCAAAA 7740 AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC GCAGTGTTAT 7800 CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC GTAAGATGCT 7860 TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGTATG CGGCGACCGA 79 0 GTTGCTCTTG CCCGGCGTCA ATACGGGATA ATACCGCGCC ACATAGCAGA ACTTTAAAAG 7980 TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACTCTC AAGGATCTTA CCGCTGTTGA 8040 GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT TTTACTTTCA 8100 CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG GGAATAAGGG 8160 CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTTCA ATATTATTGA AGCATTTATC 8220 AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT AAACAAATAG 8280 GGGTTCCGCG CACATTTCCC CGAAAAGTGC CACCTGACGT CCBRAAG 8327 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8897 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: GGTACCAATT TAAATTGATA TCTCCTTAGG TCTCGAGCAC CATGAAGTTG CCTGTTAGGC 60 TGTTGGTGCT GATGTTCTGG ATTCCTGCTT CCAGCAGTGA TGTTTTGATG ACCCAAATTC 120 CAGTCTCCCT GCCTGTCAGT CTTGGAGATC AAGCGTCCAT CTCTTGCAGA TCTAGTCAGA 180 TCATTGTACA TAATAATGGC AACACCTATT TAGAATGGTA CCTGCAGAAA CCAGGCCAGT 240 CTCCACAGCT CCTGATCTAC AAAGTTTCCA ACCGATTTTC TGGGGTCCCA GACAGGTTCA 300 GCGGCAGTGG ATCAGGGACA GATTTCACAC TCAAGATCAG CAGAGTGGAG GCTGAGGATC 360 TGGGAGTTTA TTACTGCTTT CAAGGTTCAC ATGTTCCATT CACGTTCGGC TCGGGGACAA 420 AGTTGGAAAT AAAACGTAAG TCTCGAGTCT CTAGATAACC GGTCAATCGA TTGGAATTCT 480 AAACTCTGAG GGGGTCGGAT GACGTGGCCA TTCTTTGCCT AAAGCATTGA GTTTACTGCA 540 AGGTCAGAAA AGCATGCAAA GCCCTCAGAA TGGCTGCAAA GAGCTCCAAC AAAACAATTT 600 AGAACTTTAT TAAGGAATAG GGGGAAGCTA GGAAGAAACT CAAAACATCA AGATTTTAAA 660 TACGCTTCTT GGTCTCCTTG CTATAATTAT CTGGGATAAG CATGCTGTTT TCTGTCTGTC 720 CCTAACATGC CCTTATCCGC AAACAACACA CCCAAGGGCA GAACTTTGTT ACTTAAACAC 780 CATCCTGTTT GCTTCTTTCC TCAGGAACTG TGGCTGCACC ATCTGTCTTC ATCTTCCCGC 840 CATCTGATGA GCAGTTGAAA TCTGGAACTG CCTCTGTTGT GTGCCTGCTG AATAACTTCT 900 ATCCCAGAGA GGCCAAAGTA CAGTGGAAGG TGGATAACGC CCTCCAATCG GGTAACTCCC 960 AGGAGAGTGT CACAGAGCAG GAGAGCAAGG ACAGCACCTA CAGCCTCAGC AGCACCCTGA 1020 CGCTGAGCAA AGCAGACTAC GAGAAACACA AAGTCTACGC CTGCGAAGTC ACCCATCAGG 1080 GCCTGAGCTC GCCCGTCACA AAGAGCTTCA ACAGGGGAGA GTGTTAGAGG GAGAAGTGCC 1140 CCCACCTGCT CCTCAGTTCC AGCCTGACCC CCTCCCATCC TTTGGCCTCT GACCCTTTTT 1200 CCACAGGGGA CCTACCCCTA TTGCGGTCCT CCAGCTCATC TTTCACCTCA CCCCCCTCCT 1260 CCTCCTTGGC TTTAATTATG CTAATGTTGG AGGAGAATGA ATAAATAAAG TGAATCTTTG 1320 CACCTGTGGT TTCTCTCTTT CCTCATTTAA TAATTATTAT CTGTTGTTTT ACCAACTACT 1380 CAATTTCTCT TATAAGGGAC TAAATATGTA GTCATCCTAA GGCACGTAAC CATTTATAAA 1440 AATCATCCTT CATTCTATTT TACCCTATCA TCCTCTGCAA GACAGTCCTC CCTCAAACCC 1500 ACAAGCCTTC TGTCCTCACA GTCCCCTGGG CCATGGTAGG AGAGACTTGC TTCCTTGTTT 1560 TCCCCTCCTC AGCAAGCCCT CATAGTCCTT TTTAAGGGTG ACAGGTCTTA CAGTCATATA 1620 TCCTTTGATT CAATTCCCTG AGAATCAACC AAAGCAAATT TTTCAAAAGA AGAAACCTGC 1680 TATAAAGAGA ATCATTCATT GCAACATGAT ATAAAATAAC AACACAATAA AAGCAATTAA 1740 ATAAACAAAC AATAGGGAAA TGTTTAAGTT CATCATGGTA CTTAGACTTA ATGGAATGTC 1800 ATGCCTTATT TACATTTTTA AACAGGTACT GAGGGACTCC TGTCTGCCAA GGGCCGTATT 1860 GAGTACTTTC CACAACCTAA TTTAATCCAC ACTATACTGT GAGATTAAAA ACATTCATTA 1920 AAATGTTGCA AAGGTTCTAT AAAGCTGAGA GACAAATATA TTCTATAACT CAGCAATCCC 1980 ACTTCTAGAT GACTGAGTGT CCCCACCCAC CAAAAAACTA TGCAAGAATG TTCAAAGCAG 2040 CTTTATTTAC AAAAGCCAAA AATTGGAAAT AGCCCGATTG TCCAACAATA GAATGAGTTA 2100 TTAAACTGTG GTATGTTTAT ACATTAGAAT ACCCAATGAG GAGAATTAAC AAGCTACAAC 2160 TATACCTACT CACACAGATG AATCTCATAA AAATAATGTT ACATAAGAGA AACTCAATGC 2220 AAAAGATATG TTCTGTATGT TTTCATCCAT ATAAAGTTCA AAACCAGGTA AAAATAAAGT 2280 TAGAAATTTG GATGGAAATT ACTCTTAGCT GGGGGTGGGC GAGTTAGTGC CTGGGAGAAG 2340 ACAAGAAGGG GCTTCTGGGG TCTTGGTAAT GTTCTGTTCC TCGTGTGGGG TTGTGCAGTT 2400 ATGATCTGTG CACTGTTCTG TATACACATT ATGCTTCAAA ATAACTTCAC ATAAAGAACA 2460 TCTTATACCC AGTTAATAGA TAGAAGAGGA ATAAGTAATA GGTCAAGACC AACGCAGCTG 2520 GTAAGTGGGG GCCTGGGATC AAATAGCTAC CTGCCTAATC CTGCCC CTT GAGCCCTGAA 2580 TGAGTCTGCC TTCCAGGGCT CAAGGTGCTC AACAAAACAA CAGGCCTGCT ATTTTCCTGG 2640 CATCTGTGCC CTGTTTGGCT AGCTAGGAGC ACACATACAT AGAAATTAAA TGAAACAGAC 2700 CTTCAGCAAG GGGACAGAGG ACAGAATTAA CCTTGCCCAG ACACTGGAAA CCCATGTATG 2760 AACACTCACA TGTTTGGGAA GGGGGAAGGG CACATGTAAA TGAGGACTCT TCCTCATTCT 2820 ATGGGGCACT CTGGCCCTGC CCCTCTCAGC TACTCATCCA TCCAACACAC CTTTCTAAGT 2880 ACCTCTCTCT GCCTACACTC TGAAGGGGTT CAGGAGTAAC TAACACAGCA TCCCTTCCCT 2940 CAAATGACTG ACAATCCCTT TGTCCTGCTT TGTTTTTCTT TCCAGTCAGT ACTGGGAAAG 3000 TGGGGAAGGA CAGTCATGGA GAAACTACAT AAGGAAGCAC CTTGCCCTTC TGCCTCTTGA 3060 GAATGTTGAT GAGTATCAAA TCTTTCAAAC TTTGGAGGTT TGAGTAGGGG TGAGACTCAG 3120 TAATGTCCCT TCCAATGACA TGAACTTGCT CACTCATCCC TGGGGGCCAA ATTGAACAAT 3180 CAAAGGCAGG CATAATCCAG TTATGAATTC TTGCGGCCGC TTGCTAGCTT CACGTGTTGG 3240 ATCCAACCGC GGAAGGGCCC TATTCTATAG TGTCACCTAA ATGCTAGAGC TCGCTGATCA 3300 GCCTCGACTG TGCCTTCTAG TTGCCAGCCA TCTGTTGTTT GCCCCTCCCC CGTGCCTTCC 3360 TTGACCCTGG AAGGTGCCAC TCCCACTGTC CTTTCCTAAT AAAATGAGGA AATTGCATCG 3420 CATTGTCTGA GTAGGTGTCA TTCTATTCTG GGGGGTGGGG TGGGGCAGGA CAGCAAGGGG 3480 GAGGATTGGG AAGACAATAG CAGGCATGCT GGGGATGCGG TGGGCTCTAT GGCTTCTGAG 3540 GCGGAAAGAA CCAGCTGGGG CTCTAGGGGG TATCCCCACG CGCCCTGTAG CGGCGCATTA 3600 AGCGCGGCGG GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG 3660 CCCGCTCCTT TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGGCC TCTCAAAAAA 3720 GGGAAAAAAA GCATGCATCT CAATTAGTCA GCAACCATAG TCCCGCCCCT AACTCCGCCC 3780 ATCCCGCCCC TAACTCCGCC CAGTTCCGCC CATTCTCCGC CCCATGGCTG ACTAATTTTT 3840 TTTATTTATG CAGAGGCCGA GGCCGCCTCG GCCTCTGAGC TATTCCAGAA GTAGTGAGGA 3900 GGCTTTTTTG GAGGCCTAGG CTTTTGCAAA AAGCTTGGAC AGCTCAGGGC TGCGATTTCG 3960 CGCCAAACTT GACGGCAATC CTAGCGTGAA GGCTGGTAGG ATTTTATCCC CGCTGCCATC 4020 ATGGTTCGAC CATTGAACTG CATCGTCGCC GTGTCCCAAA ATATGGGGAT TGGCAAGAAC 4080 GGAGACCTAC CCTGGCCTCC GCTCAGGAAC GAGTTCAAGT ACTTCCAAAG AATGACCACA 4140 ACCTCTTCAG TGGAAGGTAA ACAGAATCTG GTGATTATGG GTAGGAAAAC CTGGTTCTCC 4200 ATTCCTGAGA AGAATCGACC TTTAAAGGAC AGAATTAATA TAGTTCTCAG TAGAGAACTC 4260 AAAGAACCAC CACGAGGAGC TCATTTTCTT GCCAAAAGTT TGGATGATGC CTTAAGACTT 4320 ATTGAACAAC CGGAATTGGC AAGTAAAGTA GACATGGTTT GGATAGTCGG AGGCAGTTCT 4380 GTTTACCAGG AAGCCATGAA TCAACCAGGC CACCTTAGAC TCTTTGTGAC AAGGATCATG 4440 CAGGAATTTG AAAGTGACAC GTTTTTCCCA GAAATTGATT TGGGGAAATA TAAACTTCTC 4500 CCAGAATACC CAGGCGTCCT CTCTGAGGTC CAGGAGGAAA AAGGCATCAA GTATAAGTTT 4560 GAAGTCTACG AGAAGAAAGA CTAACAGGAA GATGCTTTCA AGTTCTCTGC TCCCCTCCTA 4620 AAGCTATGCA TTTTTATAAG ACCATGGGAC TTTTGCTGGC TTTAGATCTC TTTGTGAAGG 4680 AACCTTACTT CTGTGGTGTG ACATAATTGG ACAAACTACC TACAGAGATT TAAAGCTCTA 4740 AGGTAAATAT AAAATTTTTA AGTGTATAAT GTGTTAAACT ACTGATTCTA ATTGTTTGTG 4800 TATTTTAGAT TCCAACCTAT GGAACTGATG AATGGGAGCA GTGGTGGAAT GCCTTTAATG 4860 AGGAAAACCT GTTTTGCTCA GAAGAAATGC CATCTAGTGA TGATGAGGCT ACTGCTGACT 4920 CTCAACATTC TACTCCTCCA AAAAAGAAGA GAAAGGTAGA AGACCCCAAG GACTTTCCTT 4980 CAGAATTGCT AAGTTTTTTG AGTCATGCTG TGTTTAGTAA TAGAACTCTT GCTTGCTTTG 50 0 CTATTTACAC CACAAAGGAA AAAGCTGCAC TGCTATACAA GAAAATTATG GAAAAATATT 5100 CTGTAACCTT TATAAGTAGG CATAACAGTT ATAATCATAA CATACTGTTT TTTCTTACTC 5160 CACACAGGCA TAGAGTGTCT GCTATTAATA ACTATGCTCA AAAATTGTGT ACCTTTAGCT 5220 TTTTAATTTG TAAAGGGGTT AATAAGGAAT ATTTGATGTA TAGTGCCTTG ACTAGAGATC 5280 ATAATCAGCC ATACCACATT TGTAGAGGTT TTACTTGCTT TAAAAAACCT CCCACACCTC 5340 CCCCTGAACC TGAAACATAA AATGAATGCA ATTGTTGTTG TTAACTTGTT TATTGCAGCT 5400 TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA CAAATAAAGC ATTTTTTTCA 5460 CTGCATTCTA GTTGTGGTTT GTCCAAACTC ATCAATGTAT CTTATCATGT CTGGATCGGC 5520 TGGATGATCC TCCAGCGCGG GGATCTCATG CTGGAGTTCT TCGCCCACCC CAACTTGTTT 5580 ATTGCAGCTT ATAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTCAC AAATAAAGCA 5640 TTTTTTTCAC TGCATTCTAG TTGTGGTTTG TCCAAACTCA TCAATGTATC TTATCATGTC 5700 TGTATACCGT CGACCTCTAG CTAGAGCTTG GCGTAATCAT GGTCATAGCT GTTTCCTGTG 5760 TGAAATTGTT ATCCGCTCAC AATTCCACAC AACATACGAG CCGGAAGCAT AAAGTGTAAA 5820 GCCTGGGGTG CCTAATGAGT GAGCTAACTC ACATTAATTG CGTTGCGCTC ACTGCCCGCT 5880 TTCCAGTCGG GAAACCTGTC GTGCCAGCTG CATTAATGAA TCGGCCAACG CGCGGGGAGA 5940 GGCGGTTTGC GTATTGGGCG CTCTTCCGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC 6000 GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT ATCCACAGAA 6060 TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT 6120 AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA 6180 AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT 6240 CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG 6300 TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCAAT GCTCACGCTG TAGGTATCTC 6360 AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC 6 20 GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA 6 80 TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT 6540 ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC 6600 TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA 6660 CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA 6720 AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA 6780 AACTCACGTT AAGGGATTTT GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT 6840 TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC 6900 AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT TCGTTCATCC 6960 ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT ACCATCTGGC 7020 CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT ATCAGCAATA 7080 AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC 7140 CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC 7200 AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG TATGGCTTCA 7260 TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT GTGCAAAAAA 7320 GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC AGTGTTATCA 7380 CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT 7440 TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT 7500 TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG 7560 CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA GGATCTTACC GCTGTTGAGA 7620 TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT TACTTTCACC 7680 AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG 7740 ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG 7800 GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA ACAAATAGGG 7860 GTTCCGCGCA CATTTCCCCG AAAAGTGCCA CCTGACGTCG ACGGATCGGG AGATCTGCTA 7920 GCCCGGGTGA CCTGAGGCGC GCCGGCTTCG AATAGCCAGA GTAACCTTTT TTTTTAATTT 7980 TATTTTATTT TATTTTTGAG ATGGAGTTTG GCGCCGATCT CCCGATCCCC TATGGTCGAC 8040 TCTCAGTACA ATCTGCTCTG ATGCCGCATA GTTAAGCCAG TATCTGCTCC CTGCTTGTGT 8100 GTTGGAGGTC GCTGAGTAGT GCGCGAGCAA AATTTAAGCT ACAACAAGGC AAGGCTTGAC 8160 CGACAATTGC ATGAAGAATC TGCTTAGGGT TAGGCGTTTT GCGCTGCTTC GCGATGTACG 8220 GGCCAGATAT ACGCGTTGAC ATTGATTATT GACTAGTTAT TAATAGTAAT CAATTACGGG 8280 GTCATTAGTT CATAGCCCAT ATATGGAGTT CCGCGTTACA TAACTTACGG TAAATGGCCC 8340 GCCTGGCTGA CCGCCCAACG ACCCCCGCCC ATTGACGTCA ATAATGACGT ATGTTCCCAT 8400 AGTAACGCCA ATAGGGACTT TCCATTGACG TCAATGGGTG GACTATTTAC GGTAAACTGC 8460 CCACTTGGCA GTACATCAAG TGTATCATAT GCCAAGTACG CCCCCTATTG ACGTCAATGA 8520 CGGTAAATGG CCCGCCTGGC ATTATGCCCA GTACATGACC TTATGGGACT TTCCTACTTG 8580 GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT GGCAGTACAT 8640 CAATGGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC CCATTGACGT 8700 CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAAATGTC GTAACAACTC 8760 CGCCCCATTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA TAAGCAGAGC 8820 TCTCTGGCTA ACTAGAGAAC CCACTGCTTA CTGGCTTATC GAAATTAATA CGACTCACTA 8880 TAGGGAGACC CAAGCTT 8897 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8321 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GGTACCAATT TAAATTGATA TCTCCTTAGG TCTCGAGTCT CTAGATAACC GGTCAATCGA 60 TTGGAATTCT TGCGGCCGCT TGCTAGCCAC CATGGAGTTG TGGTTAAGCT TGGTCTTCCT 120 TGTCCTTGTT TTAAAAGGTG TCCAGTGTGA AGTGCAACTG GTGGAGTCTG GGGGAGGCTT 180 AGTGCAGCCT GGAGGGTCCC TGCGACTTTC CTGTGCTGCA TCTGGATTCC CGTTCAGTGA 240 CTATTACATG TATTGGGTTC GCCAGGCTCC AGGCAAGGGA CTGGAGTGGG TCTCATACAT 300 TAGTCAAGAT GGTGATATAA CCGACTATGC AGACTCCGTA AAGGGTCGAT TCACCATCTC 360 CAGAGACAAT GCAAAGAACA GCCTGTACCT GCAAATGAAC AGCCTGAGGG ACGAGGACAC 420 AGCCGTGTAT TACTGTGCAA GAGGCCTGGC GGACGGGGCC TGGTTTGCTT ACTGGGGCCA 4 BO AGGGACTCTG GTCACGGTCT CTTCCGCTAG CACCAAGGGC CCATCGGTCT TCCCCCTGGC 540 ACCCTCCTCC AAGAGCACCT CTGGGGGCAC AGCGGCCCTG GGCTGCCTGG TCAAGGACTA 600 CTTCCCCGAA CCGGTGACGG TGTCGTGGAA CTCAGGCGCC CTGACCAGCG GCGTGCACAC 660 CTTCCCGGCT GTCCTACAGT CCTCAGGACT CTACTCCCTC AGCAGCGTGG TCACCGTGCC 720 CTCCAGCAGC TTGGGCACCC AGACCTACAT CTGCAACGTG AATCACAAGC CCAGCAACAC 780 CAAGGTGGAC AAGAAAGTTG GTGAGAGGCC AGCACAGGGA GGGAGGGTGT CTGCTGGAAG 840 CCAGGCTCAG CGCTCCTGCC TGGACGCATC CCGGCTATGC AGCCCCAGTC CAGGGCAGCA 900 AGGCAGGCCC CGTCTGCCTC TTCACCCGGA GGCCTCTGCC CGCCCCACTC ATGCTCAGGG 960 AGAGGGTCTT CTGGCTTTTT CCCCAGGCTC TGGGCAGGCA CAGGCTAGGT GCCCCTAACC 1020 CAGGCCCTGC ACACAAAGGG GCAGGTGCTG GGCTCAGACC TGCCAAGAGC CATATCCGGG 1080 AGGACCCTGC CCCTGACCTA AGCCCACCCC AAAGGCCAAA CTCTCCACTC CCTCAGCTCG 1140 GACACCTTCT CTCCTCCCAG ATTCCAGTAA CTCCCAATCT TCTCTCTGCA GAGCCCAAAT 1200 CTTGTGACAA AACTCACACA TGCCCACCGT GCCCAGGTAA GCCAGCCCAG GCCTCGCCCT 1260 CCAGCTCAAG GCGGGACAGG TGCCCTAGAG TAGCCTGCAT CCAGGGACAC ACCACGTGGG 1320 TACCAACATG TCCGGAGCCA CATGGACAGA GGCCGGCTCG GCCCACCCTC TGCCCTGAGA 1380 GTGACCGCTG TACCAACCTC TGTCCCTACA GGGCAGCCCC GAGAACCACA GGTGTACACC 1440 CTGCCCCCAT CCCGGGATGA GCTGACCAAG AACCAGGTCA GCCTGACCTG CCTGGTCAAA 1500 GGCTTCTATC CCAGCGACAT CGCCGTGGAG TGGGAGAGCA ATGGGCAGCC GGAGAACAAC 1560 TACAAGACCA CGCCTCCCGT GCTGGACTCC GACGGCTCCT TCTTCCTCTA CAGCAAGCTC 1620 ACCGTGGACA AGAGCAGGTG GCAGCAGGGG AACGTCTTCT CATGCTCCGT GATGCATGAG 1680 GCTCTGCACA ACCACTACAC GCAGAAGAGC CTCTCCCTGT CTCCGGGTAA ATGAGTGCGA 1740 CGGCCGGCAA GCCCCCGCTC CCCGGGCTCT CGCGGTCGCA CGAGGATGCT TGGCACGTAC 1800 CCCCTGTACA TACTTCCCGG GCGCCCAGCA TGGAAATAAA GCACCCAGCG CTGCCCTGGG 1860 CCCCTGCGAG ACTGTGATGG TTCTTTCCAC GGGTCAGGCC GAGTCTGAGG CCTGAGTGGC 1920 ATGAGGGAGG CAGAGCGGGT CCCACTGTCC CCACACTGGC CCAGGCTGTG CAGGTGTGCC 1980 TGGGCCCCCT AGGGTGGGGC TCAGCCAGGG GCTGCCCTCG GCAGGGTGGG GGATTTGCCA 2040 GCGTGGCCCT CCCTCCAGCA GCACCTGCCC TGGGCTGGGC CACGGGAAGC CCTAGGAGCC 2100 CCTGGGGACA GACACACAGC CCCTGCCTCT GTAGGAGACT GTCCTGTTCT GTGAGCGCCC 2160 CTGTCCTCCC GACCTCCATG CCCACTCGGG GGCATGCCTA GTCCATGTGC GTAGGGACAG 2220 GCCCTCCCTC ACCCATCTAC CCCCACGGCA CTAACCCCTG GCTGCCCTGC CCAGCCTCGC 2280 ACCCGCATGG GGACACAACC GACTCCGGGG ACATGCACTC TCGGGCCCTG TGGAGGGACT 2340 GGTGCAGATG CCCACACACA CACTCAGCCC AGACCCGTTC AACAAACCCC GCACTGAGGT 2400 TGGCCGGCCA CACGGCCACC ACACACACAC GTGCACGCCT CACACACGGA GCCTCACCCG 2460 GGCGAACTGC ACAGCACCCA GACCAGAGCA AGGTCCTCGC ACACGTGAAC ACTCCTCGGA 2520 CACAGGCCCC CACGAGCCCC ACGCGGCACC TCAAGGCCCA CGAGCCTCTC GGCAGCTTCT 2580 CCACATGCTG ACCTGCTCAG ACAAACCCAG CCCTCCTCTC ACAAGGGTGC CCCTGCAGCC 2640 GCCACACACA CACAGGGGAT CACACACCAC GTCACGTCCC TGGCCCTGGC CCACTTCCCA 2700 GTGCCGCCCT TCCCTGCAGG ACGGATCAGC CTCGACTGTG CCTTCTAGTT GCCAGCCATC 2760 TGTTGTTTGC CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC CCACTGTCCT 2820 TTCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT CTATTCTGGG 2880 GGGTGGGGTG GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA GGCATGCTGG 2940 GGATGCGGTG GGCTCTATGG CTTCTGAGGC GGAAAGAACC AGCTGGGGCT CTAGGGGGTA 3000 TCCCCACGCG CCCTGTAGCG GCGCATTAAG CGCGGCGGGT GTGGTGGTTA CGCGCAGCGT 3060 GACCGCTACA CTTGCCAGCG CCCTAGCGCC CGCTCCTTTC GCTTTCTTCC CTTCCTTTCT 3120 CGCCACGTTC GCCGGGCCTC TCAAAAAAGG GAAAAAAAGC ATGCATCTCA ATTAGTCAGC 3180 AACCATAGTC CCGCCCCTAA CTCCGCCCAT CCCGCCCCTA ACTCCGCCCA GTTCCGCCCA 3240 TTCTCCGCCC CATGGCTGAC TAATTTTTTT TATTTATGCA GAGGCCGAGG CCGCCTCGGC 3300 CTCTGAGCTA TTCCAGAAGT AGTGAGGAGG CTTTTTTGGA GGCCTAGGCT TTTGCAAAAA 3360 GCTTGGACAG CTCAGGGCTG CGATTTCGCG CCAAACTTGA CGGCAATCCT AGCGTGAAGG 3420 CTGGTAGGAT TTTATCCCCG CTGCCATCAT GGTTCGACCA TTGAACTGCA TCGTCGCCGT 3480 GTCCCAAAAT ATGGGGATTG GCAAGAACGG AGACCTACCC TGGCCTCCGC TCAGGAACGA 3540 GTTCAAGTAC TTCCAAAGAA TGACCACAAC CTCTTCAGTG GAAGGTAAAC AGAATCTGGT 3600 GATTATGGGT AGGAAAACCT GGTTCTCCAT TCCTGAGAAG AATCGACCTT TAAAGGACAG 3660 AATTAATATA GTTCTCAGTA GAGAACTCAA AGAACCACCA CGAGGAGCTC ATTTTCTTGC 3720 CAAAAGTTTG GATGATGCCT TAAGACTTAT TGAACAACCG GAATTGGCAA GTAAAGTAGA 3780 CATGGTTTGG ATAGTCGGAG GCAGTTCTGT TTACCAGGAA GCCATGAATC AACCAGGCCA 3840 CCTTAGACTC TTTGTGACAA GGATCATGCA GGAATTTGAA AGTGACACGT TTTTCCCAGA 3900 AATTGATTTG GGGAAATATA AACTTCTCCC AGAATACCCA GGCGTCCTCT CTGAGGTCCA 3960 GGAGGAAAAA GGCATCAAGT ATAAGTTTGA AGTCTACGAG AAGAAAGACT AACAGGAAGA 4020 TGCTTTCAAG TTCTCTGCTC CCCTCCTAAA GCTATGCATT TTTATAAGAC CATGGGACTT 4080 TTGCTGGCTT TAGATCTCTT TGTGAAGGAA CCTTACTTCT GTGGTGTGAC ATAATTGGAC 4140 AAACTACCTA CAGAGATTTA AAGCTCTAAG GTAAATATAA AATTTTTAAG TGTATAATGT 4200 GTTAAACTAC TGATTCTAAT TGTTTGTGTA TTTTAGATTC CAACCTATGG AACTGATGAA 4260 TGGGAGCAGT GGTGGAATGC CTTTAATGAG GAAAACCTGT TTTGCTCAGA AGAAATGCCA 4320 TCTAGTGATG ATGAGGCTAC TGCTGACTCT CAACATTCTA CTCCTCCAAA AAAGAAGAGA 4380 AAGGTAGAAG ACCCCAAGGA CTTTCCTTCA GAATTGCTAA GTTTTTTGAG TCATGCTGTG 4440 TTTAGTAATA GAACTCTTGC TTGCTTTGCT ATTTACACCA CAAAGGAAAA AGCTGCACTG 4500 CTATACAAGA AAATTATGGA AAAATATTCT GTAACCTTTA TAAGTAGGCA TAACAGTTAT 4560 AATCATAACA TACTGTTTTT TCTTACTCCA CACAGGCATA GAGTGTCTGC TATTAATAAC 4620 TATGCTCAAA AATTGTGTAC CTTTAGCTTT TTAATTTGTA AAGGGGTTAA TAAGGAATAT 4680 TTGATGTATA GTGCCTTGAC TAGAGATCAT AATCAGCCAT ACCACATTTG TAGAGGTTTT 4740 ACTTGCTTTA AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA TGAATGCAAT 4800 TGTTGTTGTT AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC 4860 AAATTTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAACTCAT 4920 CAATGTATCT TATCATGTCT GGATCGGCTG GATGATCCTC CAGCGCGGGG ATCTCATGCT 4980 GGAGTTCTTC GCCCACCCCA ACTTGTTTAT TGCAGCTTAT AATGGTTACA AATAAAGCAA 5040 TAGCATCACA AATTTCACAA ATAAAGCATT TTTTTCACTG CATTCTAGTT GTGGTTTGTC 5100 CAAACTCATC AATGTATCTT ATCATGTCTG TATACCGTCG ACCTCTAGCT AGAGCTTGGC 5160 GTAATCATGG TCATAGCTGT TTCCTGTGTG AAATTGTTAT CCGCTCACAA TTCCACACAA 5220 CATACGAGCC GGAAGCATAA AGTGTAAAGC CTGGGGTGCC TAATGAGTGA GCTAACTCAC 5280 ATTAATTGCG TTGCGCTCAC TGCCCGCTTT CCAGTCGGGA AACCTGTCGT GCCAGCTGCA 5340 TTAATGAATC GGCCAACGCG CGGGGAGAGG CGGTTTGCGT ATTGGGCGCT CTTCCGCTTC 5400 CTCGCTCACT GACTCGCTGC GCTCGGTCGT TCGGCTGCGG CGAGCGGTAT CAGCTCACTC 5460 AAAGGCGGTA ATACGGTTAT CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC 5520 AAAAGGCCAG CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT TTTTCCATAG 5580 GCTCCGCCCC CCTGACGAGC ATCACAAAAA TCGACGCTCA AGTCAGAGGT GGCGAAACCC 5640 GACAGGACTA TAAAGATACC AGGCGTTTCC CCCTGGAAGC TCCCTCGTGC GCTCTCCTGT 5700 TCCGACCCTG CCGCTTACCG GATACCTGTC CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT 5760 TTCTCAATGC TCACGCTGTA GGTATCTCAG TTCGGTGTAG GTCGTTCGCT CCAAGCTGGG 5820 CTGTGTGCAC GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT 5880 TGAGTCCAAC CCGGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG GTAACAGGAT 5940 TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCTTG AAGTGGTGGC CTAACTACGG 6000 CTACACTAGA AGGACAGTAT TTGGTATCTG CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA 6060 AAGAGTTGGT AGCTCTTGAT CCGGCAAACA AACCACCGCT GGTAGCGGTG GTTTTTTTGT 6120 TTGCAAGCAG CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC 6180 TACGGGGTCT GACGCTCAGT GGAACGAAAA CTCACGTTAA GGGATTTTGG TCATGAGATT 6240 ATCAAAAAGG ATCTTCACCT AGATCCTTTT AAATTAAAAA TGAAGTTTTA AATCAATCTA 6300 AAGTATATAT GAGTAAACTT GGTCTGACAG TTACCAATGC TTAATCAGTG AGGCACCTAT 6360 CTCAGCGATC TGTCTATTTC GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAGATAAC 6420 TACGATACGG GAGGGCTTAC CATCTGGCCC CAGTGCTGCA ATGATACCGC GAGACCCACG 6480 CTCACCGGCT CCAGATTTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG AGCGCAGAAG 6540 TGGTCCTGCA ACTTTATCCG CCTCCATCCA GTCTATTAAT TGTTGCCGGG AAGCTAGAGT 6600 AAGTAGTTCG CCAGTTAATA GTTTGCGCAA CGTTGTTGCC ATTGCTACAG GCATCGTGGT 6660 GTCACGCTCG TCGTTTGGTA TGGCTTCATT CAGCTCCGGT TCCCAACGAT CAAGGCGAGT 6720 TACATGATCC CCCATGTTGT GCAAAAAAGC GGTTAGCTCC TTCGGTCCTC CGATCGTTGT 6780 CAGAAGTAAG TTGGCCGCAG TGTTATCACT CATGGTTATG GCAGCACTGC ATAATTCTCT 6840 TACTGTCATG CCATCCGTAA GATGCTTTTC TGTGACTGGT GAGTACTCAA CCAAGTCATT 6900 CTGAGAATAG TGTATGCGGC GACCGAGTTG CTCTTGCCCG GCGTCAATAC GGGATAATAC 6960 CGCGCCACAT AGCAGAACTT TAAAAGTGCT CATCATTGGA AAACGTTCTT CGGGGCGAAA 7020 ACTCTCAAGG ATCTTACCGC TGTTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA 7080 CTGATCTTCA GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA CAGGAAGGCA 7140 AAATGCCGCA AAAAAGGGAA TAAGGGCGAC ACGGAAATGT TGAATACTCA TACTCTTCCT 7200 TTTTCAATAT TATTGAAGCA TTTATCAGGG TTATTGTCTC ATGAGCGGAT ACATATTTGA 7260 ATGTATTTAG AAAAATAAAC AAATAGGGGT TCCGCGCACA TTTCCCCGAA AAGTGCCACC 7320 TGACGTCGAC GGATCGGGAG ATCTGCTAGG TGACCTGAGG CGCGCCGGCT TCGAATAGCC 7380 AGAGTAACCT TTTTTTTTAA TTTTATTTTA TTTTATTTTT GAGATGGAGT TTGGCGCCGA 7440 TCTCCCGATC CCCTATGGTC GACTCTCAGT ACAATCTGCT CTGATGCCGC ATAGTTAAGC 7500 CAGTATCTGC TCCCTGCTTG TGTGTTGGAG GTCGCTGAGT AGTGCGCGAG CAAAATTTAA 7560 GCTACAACAA GGCAAGGCTT GACCGACAAT TGCATGAAGA ATCTGCTTAG GGTTAGGCGT 7620 TTTGCGCTGC TTCGCGATGT ACGGGCCAGA TATACGCGTT GACATTGATT ATTGACTAGT 7680 TATTAATAGT AATCAATTAC GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT 7740 ACATAACTTA CGGTAAATGG CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG 7800 TCAATAATGA CGTATGTTCC CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG 7860 GTGGACTATT TACGGTAAAC TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT 7920 ACGCCCCCTA TTGACGTCAA TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG 7980 ACCTTATGGG ACTTTCCTAC TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG 8040 GTGATGCGGT TTTGGCAGTA CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT 8100 CCAAGTCTCC ACCCCATTGA CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC 8160 TTTCCAAAAT GTCGTAACAA CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG 8220 TGGGAGGTCT ATATAAGCAG AGCTCTCTGG CTAACTAGAG AACCCACTGC TTACTGGCTT 8280 ATCGAAATTA ATACGACTCA CTATAGGGAG ACCCAAGCTT G 8321 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8897 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GACGGATCGG GAGATCTGCT AGCCCGGGTG ACCTGAGGCG CGCCGGCTTC GAATAGCCAG 60 AGTAACCTTT TTTTTTAATT TTATTTTATT TTATTTTTGA GATGGAGTTT GGCGCCGATC 120 TCCCGATCCC CTATGGTCGA CTCTCAGTAC AATCTGCTCT GATGCCGCAT AGTTAAGCCA 180 GTATCTGCTC CCTGCTTGTG TGTTGGAGGT CGCTGAGTAG TGCGCGAGCA AAATTTAAGC 240 TACAACAAGG CAAGGCTTGA CCGACAATTG CATGAAGAAT CTGCTTAGGG TTAGGCGTTT 300 TGCGCTGCTT CGCGATGTAC GGGCCAGATA TACGCGTTGA CATTGATTAT TGACTAGTTA 360 TTAATAGTAA TCAATTACGG GGTCATTAGT TCATAGCCCA TATATGGAGT TCCGCGTTAC 420 ATAACTTACG GTAAATGGCC CGCCTGGCTG ACCGCCCAAC GACCCCCGCC CATTGACGTC 480 AATAATGACG TATGTTCCCA TAGTAACGCC AATAGGGACT TTCCATTGAC GTCAATGGGT 540 GGACTATTTA CGGTAAACTG CCCACTTGGC AGTACATCAA GTGTATCATA TGCCAAGTAC 600 GCCCCCTATT GACGTCAATG ACGGTAAATG GCCCGCCTGG CATTATGCCC AGTACATGAC 660 CTTATGGGAC TTTCCTACTT GGCAGTACAT CTACGTATTA GTCATCGCTA TTACCATGGT 720 GATGCGGTTT TGGCAGTACA TCAATGGGCG TGGATAGCGG TTTGACTCAC GGGGATTTCC 780 AAGTCTCCAC CCCATTGACG TCAATGGGAG TTTGTTTTGG CACCAAAATC AACGGGACTT 840 TCCAAAATGT CGTAACAACT CCGCCCCATT GACGCAAATG GGCGGTAGGC GTGTACGGTG 900 GGAGGTCTAT ATAAGCAGAG CTCTCTGGCT AACTAGAGAA CCCACTGCTT ACTGGCTTAT 960 CGAAATTAAT ACGACTCACT ATAGGGAGAC CCAAGCTTGG TACCAATTTA AATTGATATC 1020 TCCTTAGGTC TCGAGCACCA TGAAGTTGCC TGTTAGGCTG TTGGTGCTGA TGTTCTGGAT 1080 TCCTGCTTCC AGCAGTGATG TTGTCATGAC CCAAACCCCA CTGTCCAGTC CTGTCACGCT 1140 TGGACAACCT GCGTCCATCT CTTGCAGATC TAGTCAGATC ATTGTACATA ATAATGGCAA 1200 CACCTATCTG GAATGGTACC AGCAGAGACC AGGGCAGTCT CCACGGCTCC TGATCTACAA 1260 AGTTTCCAAC CGATTTTCTG GGGTCCCAGA CAGGTTCAGC GGCAGTGGAG CTGGGACAGA 1320 TTTCACACTC AAGATCAGCA GAGTGGAGGC TGAGGATGTG GGAGTTTACT ACTGCTTCCA 1380 GGGTTCACAT GTTCCATTCA CGTTCGGCCA AGGGACAAAG TTGGAAATCA AACGTAAGTC 1440 TCGAGTCTCT AGATAACCGG TCAATCGATT GGAATTCTAA ACTCTGAGGG GGTCGGATGA 1500 CGTGGCCATT CTTTGCCTAA AGCATTGAGT TTACTGCAAG GTCAGAAAAG CATGCAAAGC 1560 CCTCAGAATG GCTGCAAAGA GCTCCAACAA AACAATTTAG AACTTTATTA AGGAATAGGG 1620 GGAAGCTAGG AAGAAACTCA AAACATCAAG ATTTTAAATA CGCTTCTTGG TCTCCTTGCT 1680 ATAATTATCT GGGATAAGCA TGCTGTTTTC TGTCTGTCCC TAACATGCCC TTATCCGCAA 1740 ACAACACACC CAAGGGCAGA ACTTTGTTAC TTAAACACCA TCCTGTTTGC TTCTTTCCTC 1800 AGGAACTGTG GCTGCACCAT CTGTCTTCAT CTTCCCGCCA TCTGATGAGC AGTTGAAATC 1860 TGGAACTGCC TCTGTTGTGT GCCTGCTGAA TAACTTCTAT CCCAGAGAGG CCAAAGTACA 1920 GTGGAAGGTG GATAACGCCC TCCAATCGGG TAACTCCCAG GAGAGTGTCA CAGAGCAGGA 1980 GAGCAAGGAC AGCACCTACA GCCTCAGCAG CACCCTGACG CTGAGCAAAG CAGACTACGA 2040 GAAACACAAA GTCTACGCCT GCGAAGTCAC CCATCAGGGC CTGAGCTCGC CCGTCACAAA 2100 GAGCTTCAAC AGGGGAGAGT GTTAGAGGGA GAAGTGCCCC CACCTGCTCC TCAGTTCCAG 2160 CCTGACCCCC TCCCATCCTT TGGCCTCTGA CCCTTTTTCC ACAGGGGACC TACCCCTATT 2220 GCGGTCCTCC AGCTCATCTT TCACCTCACC CCCCTCCTCC TCCTTGGCTT TAATTATGCT 2280 AATGTTGGAG GAGAATGAAT AAATAAAGTG AATCTTTGCA CCTGTGGTTT CTCTCTTTCC 2340 TCATTTAATA ATTATTATCT GTTGTTTTAC CAACTACTCA ATTTCTCTTA TAAGGGACTA 2400 AATATGTAGT CATCCTAAGG CACGTAACCA TTTATAAAAA TCATCCTTCA TTCTATTTTA 2460 CCCTATCATC CTCTGCAAGA CAGTCCTCCC TCAAACCCAC AAGCCTTCTG TCCTCACAGT 2520 CCCCTGGGCC ATGGTAGGAG AGACTTGCTT CCTTGTTTTC CCCTCCTCAG CAAGCCCTCA 2580 TAGTCCTTTT TAAGGGTGAC AGGTCTTACA GTCATATATC CTTTGATTCA ATTCCCTGAG 2640 AATCAACCAA AGCAAATTTT TCAAAAGAAG AAACCTGCTA TAAAGAGAAT CATTCATTGC 2700 AACATGATAT AAAATAACAA CACAATAAAA GCAATTAAAT AAACAAACAA TAGGGAAATG 2760 TTTAAGTTCA TCATGGTACT TAGACTTAAT GGAATGTCAT GCCTTATTTA CATTTTTAAA 2820 CAGGTACTGA GGGACTCCTG TCTGCCAAGG GCCGTATTGA GTACTTTCCA CAACCTAATT 2880 TAATCCACAC TATACTGTGA GATTAAAAAC ATTCATTAAA ATGTTGCAAA GGTTCTATAA 2940 AGCTGAGAGA CAAATATATT CTATAACTCA GCAATCCCAC TTCTAGATGA CTGAGTGTCC 3000 CCACCCACCA AAAAACTATG CAAGAATGTT CAAAGCAGCT TTATTTACAA AAGCCAAAAA 3060 TTGGAAATAG CCCGATTGTC CAACAATAGA ATGAGTTATT AAACTGTGGT ATGTTTATAC 3120 ATTAGAATAC CCAATGAGGA GAATTAACAA GCTACAACTA TACCTACTCA CACAGATGAA 3180 TCTCATAAAA ATAATGTTAC ATAAGAGAAA CTCAATGCAA AAGATATGTT CTGTATGTTT 3240 TCATCCATAT AAAGTTCAAA ACCAGGTAAA AATAAAGTTA GAAATTTGGA TGGAAATTAC 3300 TCTTAGCTGG GGGTGGGCGA GTTAGTGCCT GGGAGAAGAC AAGAAGGGGC TTCTGGGGTC 3360 TTGGTAATGT TCTGTTCCTC GTGTGGGGTT GTGCAGTTAT GATCTGTGCA CTGTTCTGTA 3420 TACACATTAT GCTTCAAAAT AACTTCACAT AAAGAACATC TTATACCCAG TTAATAGATA 3480 GAAGAGGAAT AAGTAATAGG TCAAGACCAA CGCAGCTGGT AAGTGGGGGC CTGGGATCAA 3540 ATAGCTACCT GCCTAATCCT GCCC CTTGA GCCCTGAATG AGTCTGCCTT CCAGGGCTCA 3600 AGGTGCTCAA CAAAACAACA GGCCTGCTAT TTTCCTGGCA TCTGTGCCCT GTTTGGCTAG 3660 CTAGGAGCAC ACATACATAG AAATTAAATG AAACAGACCT TCAGCAAGGG GACAGAGGAC 3720 AGAATTAACC TTGCCCAGAC ACTGGAAACC CATGTATGAA CACTCACATG TTTGGGAAGG 3780 GGGAAGGGCA CATGTAAATG AGGACTCTTC CTCATTCTAT GGGGCACTCT GGCCCTGCCC 3840 CTCTCAGCTA CTCATCCATC CAACACACCT TTCTAAGTAC CTCTCTCTGC CTACACTCTG 3900 AAGGGGTTCA GGAGTAACTA ACACAGCATC CCTTCCCTCA AATGACTGAC AATCCCTTTG 3960 TCCTGCTTTG TTTTTCTTTC CAGTCAGTAC TGGGAAAGTG GGGAAGGACA GTCATGGAGA 4020 AACTACATAA GGAAGCACCT TGCCCTTCTG CCTCTTGAGA ATGTTGATGA GTATCAAATC 4080 TTTCAAACTT TGGAGGTTTG AGTAGGGGTG AGACTCAGTA ATGTCCCTTC CAATGACATG 4140 AACTTGCTCA CTCATCCCTG GGGGCCAAAT TGAACAATCA AAGGCAGGCA TAATCCAGTT 4200 ATGAATTCTT GCGGCCGCTT GCTAGCTTCA CGTGTTGGAT CCAACCGCGG AAGGGCCCTA 4260 TTCTATAGTG TCACCTAAAT GCTAGAGCTC GCTGATCAGC CTCGACTGTG CCTTCTAGTT 4320 GCCAGCCATC TGTTGTTTGC CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC 4380 CCACTGTCCT TTCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 4440 CTATTCTGGG GGGTGGGGTG GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA 4500 GGCATGCTGG GGATGCGGTG GGCTCTATGG CTTCTGAGGC GGAAAGAACC AGCTGGGGCT 4560 CTAGGGGGTA TCCCCACGCG CCCTGTAGCG GCGCATTAAG CGCGGCGGGT GTGGTGGTTA 4620 CGCGCAGCGT GACCGCTACA CTTGCCAGCG CCCTAGCGCC CGCTCCTTTC GCTTTCTTCC 4680 CTTCCTTTCT CGCCACGTTC GCCGGGCCTC TCAAAAAAGG GAAAAAAAGC ATGCATCTCA 4740 ATTAGTCAGC AACCATAGTC CCGCCCCTAA CTCCGCCCAT CCCGCCCCTA ACTCCGCCCA 4800 GTTCCGCCCA TTCTCCGCCC CATGGCTGAC TAATTTTTTT TATTTATGCA GAGGCCGAGG 4860 CCGCCTCGGC CTCTGAGCTA TTCCAGAAGT AGTGAGGAGG CTTTTTTGGA GGCCTAGGCT 4920 TTTGCAAAAA GCTTGGACAG CTCAGGGCTG CGATTTCGCG CCAAACTTGA CGGCAATCCT 4980 AGCGTGAAGG CTGGTAGGAT TTTATCCCCG CTGCCATCAT GGTTCGACCA TTGAACTGCA 5040 TCGTCGCCGT GTCCCAAAAT ATGGGGATTG GCAAGAACGG AGACCTACCC TGGCCTCCGC 5100 TCAGGAACGA GTTCAAGTAC TTCCAAAGAA TGACCACAAC CTCTTCAGTG GAAGGTAAAC 5160 AGAATCTGGT GATTATGGGT AGGAAAACCT GGTTCTCCAT TCCTGAGAAG AATCGACCTT 5220 TAAAGGACAG AATTAATATA GTTCTCAGTA GAGAACTCAA AGAACCACCA CGAGGAGCTC 5280 ATTTTCTTGC CAAAAGTTTG GATGATGCCT TAAGACTTAT TGAACAACCG GAATTGGCAA 5340 GTAAAGTAGA CATGGTTTGG ATAGTCGGAG GCAGTTCTGT TTACCAGGAA GCCATGAATC 5400 AACCAGGCCA CCTTAGACTC TTTGTGACAA GGATCATGCA GGAATTTGAA AGTGACACGT 5460 TTTTCCCAGA AATTGATTTG GGGAAATATA AACTTCTCCC AGAATACCCA GGCGTCCTCT 5520 CTGAGGTCCA GGAGGAAAAA GGCATCAAGT ATAAGTTTGA AGTCTACGAG AAGAAAGACT 5580 AACAGGAAGA TGCTTTCAAG TTCTCTGCTC CCCTCCTAAA GCTATGCATT TTTATAAGAC 5640 CATGGGACTT TTGCTGGCTT TAGATCTCTT TGTGAAGGAA CCTTACTTCT GTGGTGTGAC 5700 ATAATTGGAC AAACTACCTA CAGAGATTTA AAGCTCTAAG GTAAATATAA AATTTTTAAG 5760 TGTATAATGT GTTAAACTAC TGATTCTAAT TGTTTGTGTA TTTTAGATTC CAACCTATGG 5820 AACTGATGAA TGGGAGCAGT GGTGGAATGC CTTTAATGAG GAAAACCTGT TTTGCTCAGA 5880 AGAAATGCCA TCTAGTGATG ATGAGGCTAC TGCTGACTCT CAACATTCTA CTCCTCCAAA 5940 AAAGAAGAGA AAGGTAGAAG ACCCCAAGGA CTTTCCTTCA GAATTGCTAA GTTTTTTGAG 6000 TCATGCTGTG TTTAGTAATA GAACTCTTGC TTGCTTTGCT ATTTACACCA CAAAGGAAAA 6060 AGCTGCACTG CTATACAAGA AAATTATGGA AAAATATTCT GTAACCTTTA TAAGTAGGCA 6120 TAACAGTTAT AATCATAACA TACTGTTTTT TCTTACTCCA CACAGGCATA GAGTGTCTGC 6180 TATTAATAAC TATGCTCAAA AATTGTGTAC CTTTAGCTTT TTAATTTGTA AAGGGGTTAA 6240 TAAGGAATAT TTGATGTATA GTGCCTTGAC TAGAGATCAT AATCAGCCAT ACCACATTTG 6300 TAGAGGTTTT ACTTGCTTTA AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA 6360 TGAATGCAAT TGTTGTTGTT AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA 6420 ATAGCATCAC AAATTTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT 6480 CCAAACTCAT CAATGTATCT TATCATGTCT GGATCGGCTG GATGATCCTC CAGCGCGGGG 6540 ATCTCATGCT GGAGTTCTTC GCCCACCCCA ACTTGTTTAT TGCAGCTTAT AATGGTTACA 6600 AATAAAGCAA TAGCATCACA AATTTCACAA ATAAAGCATT TTTTTCACTG CATTCTAGTT 6660 GTGGTTTGTC CAAACTCATC AATGTATCTT ATCATGTCTG TATACCGTCG ACCTCTAGCT 6720 AGAGCTTGGC GTAATCATGG TCATAGCTGT TTCCTGTGTG AAATTGTTAT CCGCTCACAA 6780 TTCCACACAA CATACGAGCC GGAAGCATAA AGTGTAAAGC CTGGGGTGCC TAATGAGTGA 6840 GCTAACTCAC ATTAATTGCG TTGCGCTCAC TGCCCGCTTT CCAGTCGGGA AACCTGTCGT 6900 GCCAGCTGCA TTAATGAATC GGCCAACGCG CGGGGAGAGG CGGTTTGCGT ATTGGGCGCT 6960 CTTCCGCTTC CTCGCTCACT GACTCGCTGC GCTCGGTCGT TCGGCTGCGG CGAGCGGTAT 7020 CAGCTCACTC AAAGGCGGTA ATACGGTTAT CCACAGAATC AGGGGATAAC GCAGGAAAGA 7080 ACATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT 7140 TTTTCCATAG GCTCCGCCCC CCTGACGAGC ATCACAAAAA TCGACGCTCA AGTCAGAGGT 7200 GGCGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC CCCTGGAAGC TCCCTCGTGC 7260 GCTCTCCTGT TCCGACCCTG CCGCTTACCG GATACCTGTC CGCCTTTCTC CCTTCGGGAA 7320 GCGTGGCGCT TTCTCAATGC TCACGCTGTA GGTATCTCAG TTCGGTGTAG GTCGTTCGCT 7380 CCAAGCTGGG CTGTGTGCAC GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA 7440 ACTATCGTCT TGAGTCCAAC CCGGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG 7500 GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCTTG AAGTGGTGGC 7560 CTAACTACGG CTACACTAGA AGGACAGTAT TTGGTATCTG CGCTCTGCTG AAGCCAGTTA 7620 CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT CCGGCAAACA AACCACCGCT GGTAGCGGTG 7680 GTTTTTTTGT TTGCAAGCAG CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT 7740 TGATCTTTTC TACGGGGTCT GACGCTCAGT GGAACGAAAA CTCACGTTAA GGGATTTTGG 7800 TCATGAGATT ATCAAAAAGG ATCTTCACCT AGATCCTTTT AAATTAAAAA TGAAGTTTTA 7860 AATCAATCTA AAGTATATAT GAGTAAACTT GGTCTGACAG TTACCAATGC TTAATCAGTG 7920 AGGCACCTAT CTCAGCGATC TGTCTATTTC GTTCATCCAT AGTTGCCTGA CTCCCCGTCG 7980 TGTAGATAAC TACGATACGG GAGGGCTTAC CATCTGGCCC CAGTGCTGCA ATGATACCGC 8040 GAGACCCACG CTCACCGGCT CCAGATTTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG 8100 AGCGCAGAAG TGGTCCTGCA ACTTTATCCG CCTCCATCCA GTCTATTAAT TGTTGCCGGG 8160 AAGCTAGAGT AAGTAGTTCG CCAGTTAATA GTTTGCGCAA CGTTGTTGCC ATTGCTACAG 8220 GCATCGTGGT GTCACGCTCG TCGTTTGGTA TGGCTTCATT CAGCTCCGGT TCCCAACGAT 8280 CAAGGCGAGT TACATGATCC CCCATGTTGT GCAAAAAAGC GGTTAGCTCC TTCGGTCCTC 8340 CGATCGTTGT CAGAAGTAAG TTGGCCGCAG TGTTATCACT CATGGTTATG GCAGCACTGC 8400 ATAATTCTCT TACTGTCATG CCATCCGTAA GATGCTTTTC TGTGACTGGT GAGTACTCAA 8460 CCAAGTCATT CTGAGAATAG TGTATGCGGC GACCGAGTTG CTCTTGCCCG GCGTCAATAC 8520 GGGATAATAC CGCGCCACAT AGCAGAACTT TAAAAGTGCT CATCATTGGA AAACGTTCTT 8580 CGGGGCGAAA ACTCTCAAGG ATCTTACCGC TGTTGAGATC CAGTTCGATG TAACCCACTC 8640 GTGCACCCAA CTGATCTTCA GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA 8700 CAGGAAGGCA AAATGCCGCA AAAAAGGGAA TAAGGGCGAC ACGGAAATGT TGAATACTCA 8760 TACTCTTCCT TTTTCAATAT TATTGAAGCA TTTATCAGGG TTATTGTCTC ATGAGCGGAT 8820 ACATATTTGA ATGTATTTAG AAAAATAAAC AAATAGGGGT TCCGCGCACA TTTCCCCGAA 8880 AAGTGCCACC TGACGTC 8897

Claims: What is claimed is: 1. A method for inhibiting immunoglobulin-induced toxicity resulting from immunoglobulin immunotherapy in a subject comprising administering an immunoglobulin molecule to the subject, the immunoglobulin molecule having a variable region and a constant region, the immunoglobulin molecule being modified prior to administration by structurally altering multiple toxicity associated domains in the constant region so that immunoglobulin- induced toxicity is inhibited. 2. A method for inhibiting immunoglobulin-induced toxicity resulting from immunoglobulin immunotherapy in a subject comprising administering a structurally altered antibody to the subject, the structurally altered antibody comprising a variable region and a constant region, multiple toxicity associated domains in the constant region being modified so as to render the constant region unable to mediate an ADCC response or activate complement thereby inhibiting immunoglobulin-induced toxicity resulting from immunotherapy. A method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an Ig fusion protein to the subject, the Ig fusion protein having multiple structurally altered toxicity associated domains in the constant region. A method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an Ig fusion protein to the subject, the Ig fusion protein comprising a modified constant region, the modification being a structural alteration in multiple toxicity associated regions within the CH 2 domain. 5. A method for preventing immunoglobulin-induced toxicity resulting from immunotherapy for a disease in a subject comprising: (a) selecting an immunoglobulin which recognizes and binds a target, the target being associated with the disease; (b) mutating the immunoglobulin so selected by structurally altering multiple toxicity associated domains in the constant region of the immunoglobulin thereby creating a structurally altered immunoglobulin; (c) administering the structurally altered immunoglobulin of step (b) to the subject under conditions so that the structurally altered immunoglobulin recognizes and binds the target thereby alleviating symptoms associated with the disease, the structural alteration of the constant region thereby preventing immunoglobulin-induced toxicity in the subject. 6. A method for preventing immunoglobulin-induced toxicity resulting from immunotherapy for a disease in a subject comprising: (a) selecting an Ig fusion protein which recognizes and binds a target, the target being associated with the disease; (b) structurally altering multiple toxicity associated domains in the CH 2 domain of the constant region of the Ig protein so selected; (c) administering the structurally altered Ig fusion protein of step (b) to the subject under conditions so that the structurally altered Ig fusion protein recognizes and binds the target thereby alleviating symptoms associated with the disease, the structural alteration of the CH 2 domain thereby preventing immunoglobulin-induced toxicity in the subject. 7. The method of claim 1, 2, 3, 4, 5, or 6, wherein the portion of the constant region is the CH 2 domain. 8. The method of claim 1 or 5, wherein the immunoglobulin molecule is IgG. 9. The method of claim 1 or 5, wherein the immunoglobulin molecule is IgM. 10. The method of claim 1 or 5, wherein the immunoglobulin molecule is IgA. 11. The method of claim 2, wherein the antibody recognizes and binds Le y . 12. The method of claim 2, wherein the antibody recognizes and binds to Le x . 13. The method of claim 2, wherein the antibody is a monoclonal antibody BR96 produced by the hybridoma having the identifying characteristics of HB 10036 as deposited with the ATCC. 14. The method of claim 2, wherein the antibody is a chimeric antibody ChiBR96 produced by the hybridoma having the identifying characteristics of HB 10460 as deposited with the ATCC. 15. The method of claim 1 or 5, wherein the immunoglobulin recognizes and binds Le y . 16. The method of claim 1 or 5, wherein the immunoglobulin recognizes and binds to Le X 17. The method of claim 1 or 5, wherein the immunoglobulin is a monoclonal antibody BR96 produced by the hybridoma having the identifying characteristics of HB 10036 as deposited with the ATCC. 18. The method of claim 1 or 5, wherein the immunoglobulin is a chimeric antibody ChiBR96 produced by the hybridoma having the identifying characteristics of HB 10460 as deposited with the ATCC. 19. The method of claim 3, 4, or 6, wherein the Ig fusion protein recognizes and binds Le y . 20. The method of claim 3, 4, or 6, wherein the Ig fusion protein recognizes and binds to Le x . 21. The method of claim 3, 4, or 6, wherein the Ig fusion protein is a derivative of monoclonal antibody BR96 produced by the hybridoma having the identifying characteristics of HB 10036 as deposited with the ATCC. 22. The method of claim 3, 4, or 6, wherein the Ig fusion protein is a derivative of chimeric antibody ChiBR96 produced by the hybridoma having the identifying characteristics of HB 10460 as deposited with the ATCC. 23. A pharmaceutical composition comprising a pharmaceutically effective amount of a structurally altered immunoglobulin, and an acceptable carrier, the structurally altered immunoglobulin (1) recognizes and binds a target, the target is associated with cancer and (2) has an inactivated CH 2 domain. 24. A pharmaceutical composition comprising a pharmaceutically effective amount of structurally altered Ig fusion protein, and an acceptable carrier, the structurally altered Ig fusion protein (1) recognizes and binds a target, the target is associated with cancer and (2) has an inactivated CH 2 domain. 25. A method of treating carcinomas in vivo comprising administering to a subject a pharmaceutically effective amount of the composition of claim 23 or 24. 26. The method of claim 30, wherein the structurally altered immunoglobulin in the composition is labeled so as to directly or indirectly produce a detectable signal with a compound selected from the group consisting of a radiolabel, an enzyme, a chromophore, a chemiluminescer, and a fluorescer. 27. The method of claim 24, wherein the Ig fusion protein in the composition is labeled so as to directly or indirectly produce a detectable signal with a compound selected from the group consisting of a radiolabel, an enzyme, a chromophore, a chemiluminescer, and a fluorescer. 28. The method of claim 2 or 5, wherein the antibody is conjugated to a cytotoxic agent. 29. The method of claim 1 , wherein the immunoglobulin is conjugated to a cytotoxic agent. 30. The method of claim 3, 4 or 6, wherein the Ig fusion protein is conjugated to a cytotoxic agent. 31. The method of claim 28, 29, or 31 , wherein the cytotoxic agent is selected from the group consisting of antimetabolites, alkylating agents, anthracyclines, antibiotics, anti-mitotic agents, and chemotherapeutic agents. 32. A method for treating a subject suffering from a cancer, the cancer being characterized as a group of cells having a tumor associated antigen on the cell surface, which method comprises administering to the subject a cancer killing amount of the composition of claim 23 or 24 joined to a cytotoxic agent under conditions which permit the molecule so joined to bind the tumor associated antigen on the cell surface so as to kill the cells so bound thereby curing the subject. 33. A pharmaceutical composition comprising a pharmaceutically effective amount of a structurally altered BR96 antibody, the structurally altered antibody having an inactivated CH 2 domain. 34. A method for treating a subject suffering from a proliferative type disease characterized by cells having a BR96 antigen on the cell surface which comprises administering to the subject an effective amount of the composition of claim 33 joined to doxorubicin such that the immunoconjugate binds the BR96 antigen and kills said cells thereby treating the subject. 35. A method for inhibiting BR96 (ATCC : HB 10036) induced toxicity resulting from immunoglobulin immunotherapy in a subject comprising administering BR96 to the subject, the BR96 molecule being modified prior to administration, the modification comprising the deletion or substitution of at least one amino acid residue in the toxicity associated domain localized to amino acids 310-331 and the deletion or substitution of at least one amino acid residue in the toxicity associated domain localized to amino acids 231 - 238 so that complement and Fc receptor mediated toxicity is inhibited. 36. A method for preventing BR96 (ATCC: HB 10036) induced toxicity resulting from immunotherapy for cancer in a subject comprising: (a) mutating the BR96 polypeptide by the deletion or substitution of at least one amino acid residue in the toxicity associated domain localized to amino acids 310-331 and the deletion or substitution of at least one amino acid residue in the toxicity associated domain localized to amino acids 231 -238 so that complement and Fc receptor mediated immunoglobulin-induced toxicity is inhibited in the altered BR96 polypeptide; and (b) administering the structurally altered BR96 polypeptide of step (a) to the subject under conditions so that the peptide recognizes and binds cancer associated Le y antigens, thereby alleviating symptoms associated with the cancer, the structural alteration of the toxicity associated domains thereby preventing BR96 toxicity in the subject. 37. A chimeric BR96 antibody having a structurally altered constant region having the CHI and CH3 domains but not the CH2 domain, the antibody being designated cBR96-A. 38. The chimeric BR96 antibody of claim 37 which is expressed by the plasmid having the sequence shown in SEQ ID NO. 10. 39. A BR96 antibody having humanized variable and constant regions, wherein the constant region has been structurally altered so that the CHI and CH3 domains are present but the CH2 domain is not, the antibody being designated hBR96-2A. 40. The BR96 antibody of claim 39 which is expressed by the plasmid having the sequence shown in SEQ ID NO. 12. 41. A BR96 antibody designated hBR96-2B having a structurally altered constant region wherein leucine at amino acid position 235 is mutated to alanine and glycine at amino acid position 237 is mutated to alanine. 42. A BR96 antibody designated hBR96-2C having a structurally altered constant region wherein glutamic acid at amino acid position 318 is mutated to serine; lysine at amino acid position 320 is mutated to serine; and lysine at amino acid position 322 is mutated to serine. 43. A BR96 antibody designated hBR96-2D having a structurally altered constant region wherein proline at amino acid position 331 is mutated to alanine. 44. A BR96 antibody designated hBR96-2E having a structurally altered constant region wherein leucine at amino acid position 235 is mutated to alanine; glycine at amino acid position 237 is mutated to alanine; glutamic acid at amino acid position 318 is mutated to serine; lysine at amino acid position 320 is mutated to serine; and lysine at amino acid position 322 is mutated to serine. 45. A BR96 antibody designated hBR96-2F having a structurally altered constant region wherein leucine at amino acid position 235 is mutated to alanine; glycine at amino acid position 237 is mutated to alanine; and proline at amino acid position 331 is mutated to alanine. 46. A BR96 antibody designated hBR96-2G having a structurally altered constant region wherein glutamic acid at amino acid position 318 is mutated to serine; lysine at amino acid position 320 is mutated to serine; and lysine at amino acid position 322 is mutated to serine; and proline at amino acid position 331 is mutated to alanine. 47. A BR96 antibody designated hBR96-2H having a structurally altered constant region wherein leucine at amino acid position 235 is mutated to alanine; glycine at amino acid position 237 is mutated to alanine; glutamic acid at amino acid position 318 is mutated to serine; lysine at amino acid position 320 is mutated to serine; lysine at amino acid position 322 is mutated to serine; and proline at amino acid position 331 is mutated to alanine. 48. A nucleic acid molecule which encodes the BR96 antibody of claim 37, 39, and 41-47. 49. A cDNA of claim 48. 50. A plasmid which comprises the nucleic acid molecule of claim 48. 51. A host vector system comprising a plasmid of claim 50 in a suitable host cell. 52. A method for producing a protein comprising growing the host vector system of claim 51 so as to produce the protein in the host and recovering the protein so produced.

Inventors: ROSOK MAE JOANNE, YELTON DALE E, ROSOK, MAE, JOANNE, YELTON, DALE, E.
Applicants: SQUIBB BRISTOL MYERS CO, BRISTOL-MYERS SQUIBB COMPANY
Application year: 1997
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K47, A61P35, A61P37, C07K16, C12N1, C12N5, C12N15, C12P21